



CANCER-ASSOCIATED ISOCITRATE DEHYDROGENASE MUTATION: 

















A dissertation submitted to the Johns Hopkins University in conformity with the 


























Isocitrate dehydrogenase enzymes catalyze the oxidative decarboxylation of 
isocitrate to !-ketoglutarate. Somatic point mutations in the IDH1 gene are observed 
in glioblastoma multiforme and acute myeloid leukemia, with a hot spot identified at 
amino acid residue R132. These mutant enzymes display neomorphic activity such 
that enzymes with this mutation now catalyze the reduction of !-ketoglutarate to 2-
hydroxyglutarate. Given their tumorigenic potential, mutant IDH1 enzymes are an 
attractive drug target for cancer therapies since they possess a cancer specific 
mutation and produce a metabolite that can be used as biomarker.  
The structure of IDH1 R132H- !-ketoglutarate-NADP+ was determined to a 
resolution of 2.1 Å by x-ray crystallography, and demonstrates that the enzyme is an 
asymmetric homodimer. To determine the binding site of the small molecules A07 
and ZAG within IDH1 R132H, we determined the structure of IDH1 R132H-
isocitrate-NADP-A07 with data to 3.0 Å and that of IDH1 R132H-isocitrate-NADP-
ZAG to 3.3 Å. In both structures, the small molecules bind at an allosteric site at the 
dimer interface of the semi-open conformation of IDH1 R132H. The allosteric site 
locks the enzyme in a conformation that prevents the formation of the pre-transition 
state necessary for the enzyme to undergo catalysis. This work shows that the dimer 
interface of IDH1 has a pre-defined pocket that participates in catalysis as it 
transitions between the open and closed conformations. The temperature factor of the 
binding site area is higher than that of the other portions of the structure, suggesting 





This work shows that the preformed cavity allows for binding of IDH1 to 
allosteric inhibitors. Using a combination of high throughput screening, inhibition 
assays, and structural biology, we identified a protein-protein interface that provides 
another opportunity for structure-based drug design. 
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1. Introduction  
 
1.1 !-Decarboxylating dehydrogenase family of enzymes 
Isocitrate dehydrogenases (IDHs) belong to the "-decarboxylating dehydrogenase 
family of enzymes that catalyze pyridine dependent-dehydrogenation at the !-carbon 
followed by metal ion-dependent decarboxylation at the "-carbon of 2-hydroxyacids 
(Figure 1). Divalent cations, as well as the pyridine nucleotide cofactors, NAD+ or 
NADP+, are essential for catalysis. The metal ions, Mg2+ or Mn2+ stabilize the formation 
of the substrate complex. The cofactors are similar, the only exception being the 
phosphate group at the 2’ position of the adenylate ribose in NADP+; they serve as  
 
2-Hydroxy acid   + NAD(P)+ 2-Oxalo acid   + NAD(P)H  + H+




Figure 1. Enzymatic reaction catalyzed by !-decarboxylating dehydrogenases. 
Each member of this family of enzymes catalyzes an equivalent chemical reaction: 
dehydrogenation at the !-carbon and subsequent decarboxylation at the "-carbon. 
 
reducing equivalents for biosynthetic reactions and signal transduction pathways within 
the cell. Other members of this family include: isopropylmalate dehydrogenase, tartrate 
dehydrogenase, and homoisocitrate dehydrogenase (Figure 2) [1, 2]. These enzymes 
share a common protein fold at the nucleotide-binding site, which differs slightly from 




Isopropylmalate dehydrogenase, an NADP+-dependent dehydrogenase is essential 
for leucine biosynthesis and is expressed in bacteria, fungi, and plants [4]. It converts 
isopropylmalate to !-ketoisocaproate. Tartrate dehydrogenase plays a significant role in 
dicarboxylate and glyoxylate metabolism; it enables bacteria and plants to grow on 
acetate [2]. It produces oxaloglycolate and NADH from tartrate and NAD+, and is present 
in pseudomonads [2, 5]. Homoisocitrate dehydrogenase, another NAD+-dependent 
enzyme, catalyzes the conversion of homoisocitrate to !-ketoadipate, and is crucial for 





























isocitrate isopropylmalate tartrate homoisocitrate  
 
Figure 2. !-decarboxylating dehydrogenase substrates have similar structures.  
The substrates of these enzymes are structurally similar. Isocitrate, isopropylmalate, 
tartrate, and homoisocitrate all possess a common malate core [1]. 
 
IDHs catalyze the oxidative decarboxylation of isocitrate to !-ketoglutarate (!KG) 
and are present in many species. NADP+-dependent IDH is ubiquitously expressed in 
both prokaryotic and eukaryotic organisms and it produces NADPH and !-ketoglutarate 
(i.e. 2-oxoglutarate) for processes within the cell [7]. It supplies NADPH for the pentose 
phosphate pathway and is present in the cytosol and the peroxisomes of plants, yeast, 
mice, rats, and humans [8-11]. Only eukaryotic organisms utilize NAD+-dependent IDH 
and it is present in the mitochondria. The reaction catalyzed by this enzyme is essentially 




1.2 Enzyme regulation of IDH 
The method of regulating IDH enzyme activity differs among organisms. A single 
bifunctional protein, IDH Kinase/Phosphatase, uses cycles of protein phosphorylation 
and dephosphorylation to mediate the activity of prokaryotic NADP+-dependent IDH [12, 
13]. In E. coli, S113, is present in the active site of IDH, and undergoes phosphorylation 
to inactivate the enzyme [14]. The addition of the phosphate group prevents substrate 
binding through steric hindrance and electrostatic repulsion. The removal of the 
phosphate group by the IDH Kinase/Phosphatase restores enzymatic activity. AMP levels 
control the entire IDH phosphorylation cycle, with AMP activating IDH phosphatase 

















Figure 3. Enzymatic reaction catalyzed by Isocitrate dehydrogenase.  
IDH catalyzes the Mg2+-dependent and NADP+-dependent dehydrogenation of ICT to 
oxalosuccinate and NADPH. Mg2+-dependent decarboxylation of oxalosuccinate to !KG 
and the loss of CO2 follow. 
 
In eukaryotic systems, the affinity of IDH for isocitrate is controlled by allosteric 
regulation. In yeast, AMP allosterically activates IDH, while ATP is restrictive. In 
mammalian cells, ADP enhances the affinity of IDH for substrate, while ATP is 
inhibitory [16, 17]. This prevents IDH from catalyzing the reaction unless levels of AMP 




is diminished when cellular ratios of [NADH]:[NAD+] and [ATP]:[AMP or ADP] are 
high. Xu posits that in humans, cytosolic NADP+-dependent IDH activity is controlled by 
a self-regulatory mechanism in which secondary structural elements protrude into the 
active site and prevent substrate binding [18]. No other mechanisms of regulation have 
been described for other IDH enzymes. 
1.3 Subcellular localization and cofactor requirement of Human isoforms of IDH 
Isocitrate dehydrogenases can be divided based on their subcellular localization and 
their requirement for either NADP+ or NAD+ as cofactors. Three isoforms exist in 
humans: isocitrate dehydrogenase 1 (IDH1), isocitrate dehydrogenase 2 (IDH2), and 
isocitrate dehydrogenase 3 (IDH3). There are five genes encoding these enzymes: IDH1 
on chromosome 2q33.3, IDH2 on chromosome 15q26.1, and IDH3A on 15q25.1-q25.2, 
IDH3B on 20p13, and IDH3G Xq28 [19-22]. The NADP-dependent homologs IDH1 and 
IDH2 share considerable sequence similarity (70%) and are homodimers (Figure 4), 
whereas, IDH3 is hetero-oligomeric, and more dissimilar, with two ! subunits, one " 
subunit, and one # subunit [23, 24]. Although all three subunits participate in catalysis, 
ADP binding sites important for allosteric regulation are only found on the " and # 
subunits of IDH3 [24].  
All three isoforms serve different roles within the cell (Figure 5). IDH1 localizes 
primarily to the cytosol, but it also contains a peroxisomal targeting sequence that allows 
for import into peroxisomes [8, 25]. IDH1 is involved in cholesterol synthesis, fatty acid 
synthesis, and regulates lipid metabolism [25, 26]. It replenishes cytosolic stores of !KG 
essential for the proper functioning of !KG-dependent dioxygenases, such as prolyl 




histone demethylases (KDM). There are several dioxygenases (Table 1) present within 
the cell, and they catalyze a number of different reactions [27, 28]. In addition to !KG, 
they require oxygen and iron as cofactors, and possess enhanced activity in the presence  
 
Figure 4. IDH1 and IDH2 share considerable sequence similarity. 
Human homologs, IDH1 and IDH2, share 70% sequence similarity but are dissimilar to 
IDH3. Fully conserved amino acid residues are shaded in blue. Residues important for 
catalysis are shaded in magenta. The star over amino acid residue 132 of IDH1 and the 
analogous amino acid residue 172 of IDH2 denote hot spots. The secondary structural 
assignment above the alignment corresponds to monomer A of HsIDH1, and below the 
alignment corresponds to monomer A of HsIDH2. 
 
of ascorbate, and only function under normoxic conditions [29, 30]. Additionally, 




As such, IDH1 protects against oxidative damage and detoxifies reactive oxygen species 
(ROS) by supplying NADPH for antioxidant systems that utilize glutathione or 
thioredoxin [31-35]. 
Although both IDH2 and IDH3 reside in the mitochondria, IDH3 is thought to 
make a more significant contribution to cellular metabolism and mitochondrial function 
by providing reducing equivalents that can be oxidized for ATP production. Historically, 
IDH3 was thought to catalyze the third step of the TCA cycle and the function of these 
isoforms was not thought to be redundant. However, early work by Alp suggested the 
possible involvement of both isoforms in the TCA cycle [36]. More recent studies have 
re-examined their roles and demonstrate that when IDH3 activity is defective, IDH2 can 
compensate for this deficiency with the help of a nicotinamide-nucleotide 
transhydrogenase present in the inner membrane of the mitochondrion. This 
transhydrogenase has the ability to convert NADPH to NADH [37].  
Additionally, a recent study of individuals with retinitis pigmentosa, an inherited 
degenerative eye disease, revealed homozygous mutations occurring in IDH3B. Although 
this mutation effectively eliminates the function of IDH3, abnormalities typically 
associated with mitochondrial dysfunction such as cardiac dysrhythmias, or reduced 
muscle strength, were not observed [38]. Kinetic analysis of IDH2 and IDH3 from 
affected individuals indicated that while IDH2 enzymatic activity was normal, the 
catalytic activity of IDH3 was significantly reduced [38]. This data suggests that although 
IDH3 is crucial for normal function in the retina, IDH2 may catalyze the third step of the 
TCA cycle in other tissues. It is possible that IDH3 serves a regulatory or accessory role 
7
in tissues other than the retina. Since mutations in IDH3 have not been associated with 
cancer, we will limit our discussion from this point on to IDH1 and IDH2. 
 
 
Figure 5. Isocitrate dehydrogenases are involved in many cellular processes. 
IDHs serve different roles within the cytosol, peroxisome, and mitochondrion. They 
participate in cholesterol synthesis, lipid metabolism, and protect against ROS. These 
enzymes replenish stores of !KG for dioxygenases such as TET2 and KDM. IDHs also 




Table 1. Known and proposed roles for human "KG-dependent dioxygenases. 
Dioxygenase Process Known Proposed 
CPH Collagen Modification Stabilize Helix  
P3H Collagen Modification Helix Modification  
LH Collagen Modification Anchor Point  
TMLH Carnitine Biosynthesis FA Transport  
GBBH Carnitine Biosynthesis FA Transport  
PhyH CoA Metabolism FA Metabolism  
PHD1-3 Hypoxic Sensing Signal Degradation  
FIH Hypoxic Sensing Blocks Transcripton  
FIH Ankyrin Hydroxylation HIF Regulation Protein Degradation 
EGFH GF Hydroxylation Tumorgenesis  
JMJD Histone Demethylation Epigenetic Regulation  
JMJD6 Histone Demethylation Epigenetic Regulation  
TET2 DNA Demethylation DNA Repair Regulation 
hABH2/3 DNA Demethylation DNA Repair Regulation 
FTO DNA Demethylation Fat Metabolism Obesity 
Abbreviations include: CPH, collagen proline (4R)-hydoxylase; P3H, proline (3S)-
hydroxylase; LH, lysine hydroxylase; TMLH, trimethyl lysine hydroxylase; FA, fatty 
acid; GBBH, #-butyrobetaine hydroxylase; PhyH, phytanoyl-CoA hydroxylase; PHD1-3, 
prolyl hydroxylase domain-containing proteins 1-3; FIH, factor inhibiting HIF; EGFH, 
epidermal growth factor hydroxylase; GF, growth factor; JMJD, Jumonji domain- 
containing, hABH2/3, AlkB homologs 2 and 3; TET2, ten-eleven translocase 2; and FTO, 
fat mass and obesity associated. 
 
Additionally, a recent study of individuals with retinitis pigmentosa, an inherited 




this mutation effectively eliminates the function of IDH3, abnormalities typically 
associated with mitochondrial dysfunction such as cardiac dysrhythmias, or reduced 
muscle strength, were not observed [38]. Kinetic analysis of IDH2 and IDH3 from 
affected individuals indicated that while IDH2 enzymatic activity was normal, the 
catalytic activity of IDH3 was significantly reduced [38]. This data suggests that although 
IDH3 is crucial for normal function in the retina, IDH2 may catalyze the third step of the 
TCA cycle in other tissues. It is possible that IDH3 serves a regulatory or accessory role 
in tissues other than the retina. Since mutations in IDH3 have not been associated with 
cancer, we will limit our discussion from this point on to IDH1 and IDH2. 
1.4 Rossmann fold and common structural features of IDH enzymes 
The Rossmann fold is frequently observed in nucleotide-binding proteins and 
oxidoreductases. It consists of a six-stranded parallel "-sheet surrounded by four !-
helices, which form the nucleotide-binding domain of most oxidoreductases [39, 40]. The 
nucleotide-binding domain contains the conserved signature sequence GX1-2GXXG, in 
which X is any amino acid residue [41]. This "!"!" motif is stabilized through hydrogen 
bonding and van der Waals interactions between glycine residues on the main chain and 
the pyrophosphate of the nucleotide [41, 42]. Interestingly, there are three 
oxidoreductases: isopropylmalate dehydrogenase, tartrate dehydrogenase, and a bacterial 
NAD+-dependent IDH, which share a protein fold at the nucleotide-binding domain that 
differs slightly from this typical "!"!" motif [1, 2, 4]. 
As with other dimeric NADP+-dependent IDHs, HsIDH possesses similar topology 
and secondary structure fold with varying sequence identity (Figure 6). In humans, IDH1 




domains: large, small, and clasp. Residues 1-103 and 286-414 make up the large domain 
and contain the Rossmann fold. The small domain consists of amino acid residues 104-
136 and 186-285, which form an !/" sandwich. A "-sheet joins the large and small 
domains together and two clefts flank either side of the "-sheet. The active site cleft is 
formed by residues from the large and small domains of one subunit, and the small 
domain of the adjacent subunit. There are two independent active sites present in 
homodimeric IDHs; and more than likely, a dimer is the functional unit necessary for 
catalysis. Two stacked, two-stranded anti-parallel " sheets consisting of residues 137-
185, form the clasp domain that interlocks the two subunits together, and frames the 
active site. This domain varies among species in primary sequence, as well as three-
dimensional structure of NADP+-dependent IDHs. In EcIDH, the two clasp domains form 
two anti-parallel !-helices with a four-stranded anti-parallel "-sheet, and in S. cerevisiae 
two stacked layers of four-stranded anti-parallel "-sheets are formed, whereas in 
mammalian cells, the clasp domains form one layer of four-stranded anti-parallel "-
sheets.  
1.5 Catalytic mechanism of IDH 
Residues from the large and small domains of one subunit, and the small domain of 
the adjacent subunit constitute each active site. There are binding sites for both ICT and 
NADP+, but there is no data to support concerted binding, or to suggest that the binding 
of one influences the binding of the other. Biochemical and structural studies have 
demonstrated that eukaryotic IDH undergo conformational changes upon substrate 
binding and release. The states are described as open when IDH is bound to the cofactor 




addition of divalent metal (Mg2+, Ca2+, and Mn2+). Structures of both open and closed 
forms of IDH have been determined with a productive Michaelis-Menten complex only 
formed in the closed state. A pseudo-Michaelis-Menten complex has been observed in 
the presence of product, either ICT for wild type IDH, or !KG in the case of mutant IDH. 
Closed catalytically active structures have been determined for wild type IDH1 and 
mutant forms of IDH1 [18, 43]. 
The proposed reaction mechanism is based on structural studies of SsIDH and 
HsIDH [18, 44]. There is great sequence similarity (70%) between these two species and 
many residues are conserved (Figure 6). The reaction is believed to occur in two steps: 
the oxidation of isocitrate to oxalosuccinate, followed by the loss of a carboxylate group 
from oxalosuccinate, and protonation of the "-carbon to form !-ketogutarate [45, 46]. 
The first step involves proton abstraction of the C2 hydroxyl of ICT and transfer of the 
hydride ion to the C4 of the nicotinamide ring of NADP+ (Figure 7). Several aspartate 
residues have emerged as possible general base candidates responsible for the initial 
proton abstraction in studies of EcIDH and SsIDH [3, 47]. Others postulate that active-
site water molecules are responsible for the initial proton abstraction, and coordinate with 
aspartate residues [44]. Arginine residues form a catalytic triad (SsIDH numbering, R101, 
R110, and R133) that promotes the initial proton abstraction by lowering the pKa of the 
metal-bound hydroxyl of ICT [24, 48]. The aspartate residues (HsIDH numbering, D252, 
D275, and D279) coordinate the divalent metal ion.  
The transition state undergoes electrostatic stabilization by the magnesium ion; it 
serves as a counterbalance for the negative charge formed on the hydroxyl oxygen during 




hypothesis was later confirmed by Laue structure determination [45, 49]. In the second 
step of the reaction, the "-carboxylate of the oxalosuccinate intermediate is released as 
CO2 and replaced by a proton to form the final product, !-ketogutarate. Mutational 
studies of SsIDH also suggest that T78 or S95 (HsIDH numbering, T77 or S94) assist in 
generating a good leaving group [50].  
Still, the actual mechanism of the final protonation step is unclear. In initial studies 
of SsIDH, Y140 was thought to function as the general acid that protonates the substrate 
following decarboxylation of oxalosuccinate [48]. Site-directed mutational studies of 
SsIDH suggest that a lysine residue (SsIDH numbering, K212) is essential for this step 
and stabilizes the carbanion formed by the decarboxylation of the substrate [48]. 
Additionally, the tyrosine is more likely to act as a general base in the reaction. In 
structural studies of EcIDH, Y160 supports this claim, and seems to be essential for the 
dehydrogenation step [51]. However, the possibility remains that Y139 (HsIDH 
numbering) is important for the protonation of "-carbon following the decarboxylation 
step. Although the reaction mechanism of IDH is well characterized, questions still 






Figure 6. Eukaryotic IDH enzymes possess great structural similarity. 
Structure-guided sequence comparison of homodimeric IDH enzymes: HsIDH (human), 
SsIDH (porcine), and ScIDH (yeast) using HsIDH numbering. Fully conserved amino 
acid residues are shaded in blue. Residues important for catalysis are shaded in magenta. 































































Figure 7. Proposed mechanism for reaction catalyzed by isocitrate dehydrogenase. 
The reaction begins with proton abstraction followed by hydride transfer to the C4 of the 
nicotinamide ring of NADP+ to form the intermediate, oxalosuccinate. In the second step, 
the carboxylate group leaves as CO2 and a proton replaces it at the "-carbon to form !-
ketoglutarate. The transition states are stabilized by Mg2+ coordination. HsIDH 




2. Links Between Cellular Metabolism and Cancer 
 
2.1 Historical perspective 
Since 1927, defects in mitochondrial function have been associated with tumor 
development and progression. Warburg hypothesized that disruptions in cellular 
respiration were not only associated with cancer, but were sufficient to drive oncogenesis. 
He observed that cancer cells converted glucose to lactate at a much higher rate than 
normal cells even in the presence of oxygen, and this observation became known as the 
‘Warburg Effect’ [52-54]. There are four possible fates of glucose once it enters the cell: 
anaerobically oxidized to pyruvate, shunted into the pentose phosphate pathway, stored 
as glycogen, or completely oxidized to carbon dioxide and water. Nevertheless, even 
under normoxic conditions, cancer cells rapidly consume glucose, preferentially 
converting it to lactate, rather than undergoing oxidative phosphorylation to obtain the 
maximal amount of ATP [55]. Imaging techniques like positron emission tomography 
exploit the fact that tumors have increased glucose uptake and radiologists have been able 
to detect and map tumors with great sensitivity using this technique. Evidence also 
suggests that more aggressive tumors have a higher glycolytic flux, with poor patient 
prognosis correlating with higher glucose uptake by tumors in comparison to normal 
tissues [56, 57].  
Aerobic glycolysis is widely accepted as a common feature of cancer cells and has 
been confirmed in both primary and metastatic tumors. However, it is difficult to provide 




59]. Although the cell needs energy, it also requires macromolecules. Perhaps the major 
function of aerobic glycolysis is to provide the cell with glycolytic intermediates for 
carbon skeletons, energy, and reducing equivalents to facilitate cell division and 
proliferation. By diverting glucose to other biosynthetic pathways, it enables the cell to 
generate glycerol for lipogenesis or produce NADPH and ribose-5-phosphate for 
nucleotide and nucleic acid biosynthesis, while also creating a stockpile of intermediates 
that can serve as precursors for other pathways. 
Historically, genes that cause neoplasia or tumorigenesis are grouped into one of 
two classes: tumor suppressors or oncogenes. In the case of tumor suppressor genes, 
inactivating mutations would cause a dominant loss of function that inhibits activity; 
whereas, activating mutations would cause a gain of function or result in new activity, 
and are associated with oncogenes. Typically, oncogenes possess recurrent mutations at 
the same amino acid residues; whereas, tumor suppressor genes are characterized by 
mutations throughout the entire length of the gene, that alter or truncate the encoded 
protein [60]. Oncogenes can be activated by mutations, chromosomal rearrangements, or 
gene amplifications. They encode proteins involved in cell proliferation and apoptosis 
such as, transcription factors, growth factors, and apoptosis regulators, and can affect the 
regulation or the structure of the protein encoded by that particular gene. 
Based on the classical two-hit hypothesis put forth by Knudson, mutations in tumor 
suppressor genes were believed to be recessive and affecting both alleles [61]. These 
genetic disruptions caused their inactivation and led to an overall loss of function. 
However, over time this view has expanded to include mutated tumor suppressor genes 




Haploinsufficiency arises when there are alterations in gene dosage, such that one allele 
is defective, and the other functional allele is insufficient to sustain normal function. It is 
difficult to distinguish haploinsufficiency from dominant negative mutations because in 
both cases the wild-type (WT) allele is retained. However, in the case of dominant 
negative mutations, mutant gene products recombine with normal WT gene products 
inactivating them and making non-functional complexes that contain both mutant and 
WT proteins. Malignant transformation is a multi-step process arising from genetic 
mutations, epigenetic alterations, cell signaling defects, and other perturbations, that 
confer a selective growth or survival advantage to the cell [62]. 
Warburg’s theory that mitochondrial dysfunction causes tumor growth and can 
account for the aerobic glycolysis observed in tumors is still a subject of much debate. 
Over the years, there has been a shift from viewing oncogenesis as simply a derangement 
of bioenergetics, to a multifaceted disease caused by the convergence of several factors. 
Distinct metabolic differences exist between cancer cells and normal cells, and 
mitochondrial dysfunction has come to the fore once again. Although cellular metabolism 
is not defined as a hallmark of cancer, recent studies suggest causal links between 
metabolic alterations and oncogenesis.  
2.2 Germline mutations in TCA cycle intermediates 
The notion that tumor suppressors and oncogenes can affect the activity and 
expression of metabolic enzymes has been held for quite some time [59, 63]. Germline 
mutations in genes that encode tricarboxylic acid (TCA) cycle enzymes have been 
implicated in several familial cancer cases. The TCA cycle involves a series of enzyme-




(SDH), and fumarate hydratase (FH), are sequential enzymes in this cycle. SDH is a 
heterotetramer that oxidizes succinate to fumarate, and it is also a component of the 
electron transport machinery, mitochondrial complex II. It resides in mitochondrial 
membranes and is also responsible for reducing ubiquinone to ubiquinol. Each subunit is 
encoded by a different gene and heterozygous mutations in SDHA, SDHB, SDHC, and 
SDHD all result in the complete loss of heterozygosity, (i.e. loss of remaining wild type 
allele in somatic cells), and render the gene product of SDH completely inactive [64-66]. 
Individuals with mutations in SDHB and SDHC are afflicted with papillary thyroid 
carcinomas and renal cell cancers, while mutations in SDHD present in gastrointestinal 
stromal tumors, and colorectal carcinomas. Recent findings indicate that mutations in 
SDHA cause paragangliomas and pheochromocytomas [67], as well as neurodegenerative 
disease [68]. 
Fumarate hydratase (FH) is a homotetramer that catalyzes the hydration of 
fumarate to malate. In humans a single gene, FH, encodes two splice variants. The longer 
form localizes to the mitochondria and participates in TCA cycle, while the shorter form 
resides in the cytosol and participates in purine synthesis and the urea cycle. Individuals 
harboring rare heterozygous germline mutations in FH developed leiomyomatosis of the 
skin and uterus, and renal cell carcinomas [69-71]. All mutations described above for 
fumarate hydratase and succinate dehydrogenase greatly reduce enzymatic activity and 
lead to a loss of function [72]. Both FH and SDH have been identified as classical tumor 
suppressor genes.  
The dysfunction of these enzymes and how they drive tumorigenesis is still an area 




tumorigenesis is by provoking a pseudohypoxic response. Pseudohypoxia is the abberant 
activation of the hypoxic response. HIF1, hypoxia inducible factor 1, is a transcription 
factor responsible for mediating the adaptive response to hypoxia and upregulating genes 
involved in apoptosis, cell survival, and angiogenesis [73-75]. Under hypoxic conditions 
transcription of these genes is activated and increased expression of HIF1! has been 
connected to cancer [75, 76]. In the presence of oxygen, dioxygenases will add hydroxyl 
groups to HIF1! and HIF2!, targeting them for ubiquitination and proteasomal 
degradation [77]. However, under hypoxic conditions, in the absence of oxygen, these 
hydroxylation events cannot occur, enabling HIF1! and HIF2! to form dimers with 
HIF1" and coordinate the hypoxic response. The abnormal accumulation of the 
intermediates, succinate or fumarate, can cause the inhibition of HIF prolyl hydroxylases, 
and lead to the stabilization of HIF1! [69]. These initial studies sparked renewed interest 
in how mitochondrial dysfunction could lead to tumorigenesis. More recent data on 
mutations affecting another TCA cycle enzyme, IDH, strongly support the notion that 
defects in cellular metabolism directly contribute to the progression of gliomas. 
2.3 Classification of gliomas, common features, and treatment options 
There are 69, 720 estimated new cases of malignant brain tumors that are expected 
to be diagnosed in the United States in 2013. The annual incidence rate of malignant 
brain tumors is approximately 7.3 cases per 100,000 people [78]. Gliomas, 
neuroectodermal tumors derived from glial cells, encompass more than 70% of all tumors 
affecting the central nervous system and can be classified according to histological 
subtype or tumor grade (Figure 8). Most tumors arise in the subcortical region of the 




hemispheres of adults are termed diffuse gliomas due to their propensity to infiltrate early 
and extensively throughout the brain parenchyma [79].” When classified by histological 
appearance there are three main subtypes: oligodendrogliomas and oligoastrocytomas, or 
tumors which possess morphological features of both. Additionally, the World Health 
Organization (WHO) classifies gliomas in one of four categories based on the degree of 
malignancy [80]. Grade I are slow growing and benign pilocytic astrocytomas, grade II 
are invasive diffuse astrocytomas, and grade III are anaplastic astrocytomas. Both grades  
 
 
Figure 8. Distribution of primary brain and CNS cancers. 
In terms of distribution by histological subtype and WHO classification, gliomas account 
for 75% of all brain cancers within the United States. Within this subgroup of primary 
brain and CNS cancers, glioblastomas account for more than 50% of all subtypes. 
Gliomas include: diffuse astrocytomas, oligodendrogliomas, anaplastic astrocytomas, and 
glioblastomas. Distribution based on study with N = 92,504 [78].  
 
II and III possess the ability to progress to a higher grade, with grades III and IV 
considered to be malignant, and grade IV, glioblastoma multiforme (GBM), being the 




GBM can present in one of two ways: primary lesions arise de novo, whereas 
secondary formation involves progressive transformation from a pre-existing lower grade 
II diffuse astrocytoma, or grade III anaplastic astrocytoma, to a higher grade lesion. 
Furnari states that GBM are particularly difficult to treat given their “significant 
intratumoral heterogeneity on the cytopathological, transcriptional, and genomic levels 
[79].” These diffuse, intracranial tumors almost always recur following surgery, and are 
characterized by altered cellular differentiation, apoptotic resistance, necrotic lesions, 
genomic instability, and robust neovascularization.  
Angiogenesis or neovascularization is a well-known hallmark of tumorigenesis, 
and many studies have demonstrated that it is crucial for solid tumor growth [81, 82]. As 
lesions progress from lower to higher grade, increased microvascular density, or the 
creation of a dense, tortuous network of microvessels, is a common feature [81, 83]. A 
pathological phenotype of both primary and secondary glioblastomas is microvascular 
hyperplasia. It consists of rapidly proliferating endothelial cells that emerge from normal 
microvessels as microaggregates, carrying with them components of the basal lamina 
necessary for angiogenesis [84]. This abnormal tumor vasculature greatly restricts 
oxygen delivery and also negatively impacts the efficacy of radiation therapy. Among 
solid tumors, glioblastomas in particular are highly vascularized, and there are high levels 
of the protein, vascular endothelial growth factor (VEGF), expressed in both the serum 
and the lesion [85]. VEGF stimulates the growth of new blood vessels and maintains 
tumor vasculature [86]. The overexpression of VEGF is usually indicative of a shorter 
survival rate [87], and it is also thought to be a contributing factor in the vascular cerebral 
edema observed in patients with brain cancer [88]. 
22
Figure 9. Glioblastoma multiforme development pathway. 
The neoplastic transformation from disease-free tissue to malignant glioma is displayed:
(A) normal glial tissue, (B) low grade I or grade II astrocytoma, (C) grade III anaplastic 
astrocytoma, (D) grade IV glioblastoma multiforme [89]. 
Although phenotypically similar, primary and secondary GBM associate with 
different genetic aberrations and arise from distinct molecular pathways, despite their 
indistinguishable histology. Primary GBM typically occur in older populations, with 
individuals above the age of forty-five, and associate with mutations in PTEN
(phosphatase tensin homolog), a tumor suppressor gene often inactivated in cancer. 
Additionally, loss of heterozygosity across the majority of chromosome 10, is also 
observed for primary GBM, as well as amplification of MDM2, an E3 ubiquitin ligase
whose upregulation allows for escape from p53 suppression, and EGFR, a receptor 
tyrosine kinase that controls cell proliferation [90].  
Secondary GBM affect younger populations below the age of forty-five, associate
with a loss of heterozygosity on the long arm of chromosomes 10, 19, and 22, or the loss 
of tumor suppressor genes on chromosomes 9p or 13q, as well as TP53 mutations [90-
93]. TP53 is a tumor suppressor gene whose normal response to DNA damage involves
cell cycle arrest and triggering apoptosis, but mutations render it inactive. Additionally, 
hypermethylation of CpG islands on cancer-specific gene promoters can result in 




(CIMP) is associated with glioma subtypes [94], with secondary glioblastoma displaying 
a higher frequency of methylation than any other glioma subtype [95-97].  
Despite advances with surgical resection and radiation therapy, barriers to effective 
treatment still exist. Treatment options vary depending on tumor subtype and whether the 
disease is newly diagnosed or recurrent (Table 2). The standard of care for newly 
diagnosed anaplastic astrocytomas and anaplastic oligodendrogliomas, involves maximal 
surgical resection followed by radiation therapy, and in some instances, chemotherapy is 
offered as an alternative approach [98]. It is interesting to note that patients with 
anaplastic oligodendrogliomas and anaplastic oligoastrocytomas, that also present with 
codeletion of chromosome arms, 1p and 19q, respond better to treatment and are more 
sensitive to chemotherapy in comparison to those without this codeletion [99]. Treatment 
for newly diagnosed glioblastomas involves maximal surgical resection, followed by 
post-operative radiation, and chemotherapy with temozolomide (TMZ) [98, 100]. TMZ is 
an alkylating agent that adds methyl groups to DNA purine bases, thereby damaging 
DNA, and eventually triggering an apoptotic response. Patients treated with TMZ 
following radiation therapy have prolonged survival rates and delayed tumor progression, 
in comparison to those only treated with radiation [98, 100]. 
Complete surgical resection is not always possible given the infiltrative nature of 
gliomas and there is a high rate of recurrence among patients. A PCV combination 
regimen can be administered in cases of recurrent anaplastic oligodendroglioma. 
However, the chemotherapeutic agent most commonly used in cases of recurrent disease 
is TMZ. It can be dispensed to patients with recurrent anaplastic astrocytoma, anaplastic 





Table 2. Summary of current treatment options for malignant gliomas. 
Tumor Type Standard Treatment Alternatives 
Newly diagnosed glioma   
Anaplastic oligodendroglioma Maximal surgical resection; RT TMZ or PCV 
Anaplastic astrocytoma Maximal surgical resection; RT RT/TMZ; 
   Carmustine/RT 
Glioblastoma Maximal surgical resection; RT; Modified RT; 
 TMZ or RT/TMZ 
Recurrent disease   
Anaplastic oligodendroglioma Reoperation in selected patients Irinotecan; 
 or PCV; concurrent TMZ  Erlotinib; 
  Gefitinib; or 
  Imatinib 
Anaplastic astrocytoma Reoperation or TMZ PCV 
Glioblastoma Reoperation or TMZ Procarbazine 
Abbreviations: RT, radiation therapy; PCV regimen, procarbazine, lomustine, vincristine. 
The survival rates for individuals with malignant gliomas, especially those with 
GBM, remain particularly low and are associated with disproportionately high morbidity 
and mortality (Figure 10). The median survival rate for patients with glioblastomas is 9-
15 months with less than 5% surviving for more than five years [98, 101]. This survival 
rate is only slightly longer for those with anaplastic gliomas, 2-5 years [100, 101]. 
Concurrent radiation therapy and TMZ treatment has had a certain measure of success; 






Figure 10. Glioblastomas are associated with high morbidity and mortality. 
Overall survival in trial of temozolomide in conjunction with radiation therapy (TMZ/ 
RT) versus RT alone. Randomized phase III trial comparing initial therapy of RT alone 
with RT and concomitant maintenance with TMZ [100]. 
 
methylguanine methyltransferase (MGMT) is a DNA excision repair enzyme that targets 
and removes alkyl groups that have been added to the guanine bases of DNA. When 
MGMT is amplified and overexpressed in gliomas it can reverse the effects of TMZ 
[103]. Although progress has been made with tumor detection, surgical techniques, 
radiosensitizers, angiogenesis inhibitors, chemotherapeutic drugs, and gene therapy, no 
single class of agents possessing superior efficacy against gliomas has emerged. Of late, 
studies are focusing more attention on finding new targets for treatment, by obtaining a 
better understanding of the molecular pathogenesis of this disease. 
2.4 Role of isocitrate dehydrogenase mutations in cancer 
An initial study in 2006 identified somatic mutations of IDH1 in colorectal cancer 
[104]. A subsequent study by Parsons et al. uncovered somatic mutations in IDH1 
occurring in over 12% of glioblastomas during a genome-wide mutational analysis 




which adenine was substituted for guanine (G395A), resulting in the replacement of 
arginine with a histidine at amino acid 132 (R132H), a residue thought to be important 
for catalysis. This was the most prominent amino acid substitution with other 
substitutions (R132C, R132S) occurring less frequently [105]. Additional sequencing 
efforts have uncovered aberrations in IDH that resulted in other malignancies (Table 3), 
and these include: T-cell lymphomas, prostate carcinomas, cholangiocarcinomas, 
pheochromocytomas, enchondromas, paragangliomas, spindle cell hemagiomas, 
chondrosarcomas, B-cell acute lymphoblastic leukemias, colon cancer, 
myeloproliferative neoplasms, melanomas, and thyroid carcinomas [106-112].  
2.4.1 Prevalence of IDH mutations in gliomas and acute myeloid leukemia 
Mutations in IDH1 or IDH2 are highly associated with gliomas and acute myeloid 
leukemia (AML). All mutations share these common features: somatic, monoallelic with 
one wild type allele being retained, and involve the substitution of an arginine residue at a 
recurrent position. Studies with large cohorts underscored a high prevalence of IDH 
mutations associating with gliomas and AML. They occur in 50% - 94% of grade II and 
grade III gliomas, and in 73% - 88% of secondary glioblastomas [107, 113-119]. Mutant 
IDH1 has also been identified to a lesser extent in 8% of acute myeloid leukemia (AML) 
cases [118].  
In other cancer genome studies, IDH2 mutations were found to be more common in 
AML than gliomas, occurring in 20% of cases of AML [120]. Individuals lacking point 
mutations in IDH1 at R132 will often have analogous mutations in IDH2 at R172, with 
R172K being the most prominent substitution and R172W occurring far less frequently. 




[110, 115, 120-124]. IDH2 mutations at R140 have also been reported with R140Q being 
the most prominent (95%), while R140L and R140W substitutions are less common 
[120]. Mutations at this position only occur in this tumor type. 
 
 
Figure 11. Mutations in IDH1 and IDH2 are prevalent in gliomas and AML. 
Mutations of IDH1 are more prevalent in gliomas while mutations in IDH2 are more 
prominent in cases of AML. There is a hot spot located at R132H on IDH1 and an 
analogous hot spot at R172K located on IDH2. [125]. 
 
IDH mutations may predispose cells to become malignant since they occur before 
the development of other aberrations [117, 126]. Histological analysis of paired samples 
in glioma patients transforming from low-grade to high-grade lesions showed aberrations 
in IDH were early events in tumor progression [118]. Surprisingly, mutations in IDH1 or 
IDH2 have not been observed in primary GBM, and are generally not seen in other 
cancers of the central nervous system [114, 116, 117]. IDH mutations often segregate 
with loss of chromosomal arms 1p and 19q in the majority of diffuse gliomas [127]. As it 




IDH tend to have a better prognosis than those with wild type IDH (Figure 12). Overall, 
their median survival rate tends to be longer [116, 119, 128-130]. Although these 
prognostic results are interesting, there are no reports that clearly define IDH mutations 
as significant predictive indicators of disease progression or lack thereof.  
2.4.2 Neomorphic activity of Human IDH mutants 
Mutant forms of IDH1 and IDH2 lose their ability to convert isocitrate to !KG 
through oxidative decarboxylation. Following this observation, Yan and colleagues were 
the first to assert that the R132H mutation in IDH1 and the R172K mutation in IDH2 
result in a loss of enzymatic function [119]. Subsequent studies verified this loss of 
function, and suggested that IDH1 was a tumor suppressor gene displaying dominant 
negative activity, as mutant IDH1 formed heterodimers with wild type IDH1. [131].  
Zhao postulated that the formation of catalytically inactive heterodimers could lead to the 
inactivation of IDH1, causing a reduction in !KG levels within the cell, and inducing 
HIF1-! to activate target genes and drive tumorigenesis. However, this hypothesis was 
challenged by other reports that demonstrated that mutant heterodimers (WT:R132H) do 
not exhibit dominant negative inhibition, nor are they formed in excess of wild type or 
mutant homodimers [132, 133]. Additionally, these mutations were not observed to be 
sufficient to upregulate HIF1-!. Dang and colleagues put forward another hypothesis and 
reported a novel gain of function [43]. 
IDH mutants possess neomorphic enzyme activity (Figure 13) and catalyze the 






Table 3. Somatic IDH1 and IDH2 mutations were identified in different tumors. 
Tumor Type IDH1 IDH2 References 
Glioma R132H R172K [43, 105, 113, 114, 116, 117, 
119] 
 R132C R172M  
 R132S R172S  
 R132G R172G  
 R132L R172W  
 R132V   
Acute myeloid leukemia R132H R140Q [110, 115, 118, 120-124] 
 R132G R172K  
 R132C R140W  
 R132S R172G  
 R132L R140L  
 V71I   
Prostate carcinoma R132H  [107] 
 R132C   
$-cell acute lymphoblastic 
leukemia 
R132H  [107] 
Paraganglioma R132C  [112] 
 R132H   
Colon cancer R132C  [104, 107, 114] 
Thyroid carcinoma V71I  [111] 
 G123R   
Chondrosarcoma R132C R172S [106] 
 R132H   
 R132G   
Enchondroma R132H R172K [109] 
Cholangiocarcinoma R132C R172W [108, 134] 
 R132L   




behaves more like an oncogene than a tumor suppressor. This study was the first to report 
the production of the oncometabolite, 2HG, accumulating to unusually high, millimolar 
concentrations within cells, from the NADPH-dependent reduction of !KG [43]. This and 
subsequent studies demonstrated that IDH1 mutants (R132H, R132C, R132L, R132S, 
R132G, R132V) and IDH2 mutants (R172K, R172M, R172S, R172G, R172W) all 
possess the ability to reduce !KG to 2HG [43, 121, 122, 124, 132].  
Different research groups performed mass spectrometry analysis and were able to 
confirm 2HG as the direct product of these mutant enzymes [43, 122, 124]. Vogelstein 
and colleagues regard IDH as an oncogene and more specifically, a Mut-driver gene. 
Mut-driver genes contain mutations that directly or indirectly confer a selective growth 
advantage to cells [60]. Possible mechanisms are emerging that connect the accumulation 
of 2HG with impaired dioxygenase activity and altered epigenetic regulation. 
2.4.3 Tumorigenic potential of 2-hydroxyglutarate accumulation 
Although countless cancer genome studies identified mutations in IDH genes, only 
recently has the underlying mechanism of how these mutations drive tumorigenesis been 
described. The metabolic product of mutant IDH is 2-hydroxyglutarate (2HG) and 
structurally, 2HG and !KG are nearly identical. The only exception is that the carbonyl 
group at the C2 position in !-ketoglutarate is replaced by a hydroxyl group in 2HG. This 
oncometabolite competes with !KG-dependent dioxygenases for cytosolic stores of !KG, 
and this superfamily of dioxygenases is responsible for catalyzing several different 
reactions within the cell [29]. Mutations in IDH1/IDH2 promote tumorigenesis through 






Figure 12. Patients with IDH1 mutation have better prognosis. 
(A) Overall survival curves and (B) progression-free survival curves in glioblastoma 
according to IDH1 codon 132 status (gold line, mutated; blue line, nonmutated). (C) 
Overall survival curves and (D) progression-free survival curves in grade 3 gliomas 
without 1p19q codeletion and no EGFR amplification according to IDH1 codon 132 
status (gold line, mutated; blue line, nonmutated) [136]. 
 
2HG exerts tumorigenic potential (Figure 14) by impairing the activity of prolyl 
hydroxylases, the TET family of DNA hydroxylases, and members of the Jumonji family 
of histone lysine demethylases (KDM). It has deleterious effects on several processes 
within the cell, including the hypermethylation of DNA and chromatin [135, 137]. These 
alterations cause epigenetic reprogramming, and ultimately lead to tumorigenesis. 
Additionally, prolyl hydroxylases (PHDs) regulate the activity of HIF proteins by adding 
hydroxyl groups to key proline residues. The stability and activity of HIF1! is also 
affected by ROS and intracellular levels of !KG [138]. There is some debate as to 




hydroxylases and lead to the stabilization of HIF1!. Studies probing the effects of 2HG 
accumulation on PHDs and HIF activity have yielded conflicting in vitro results. Some 
studies demonstrate that 2HG acts as a PHD inhibitor and results in the expression of 
more HIF protein, with less targeting of HIF protein for proteasomal degradation [137]. 
Still other reports provide evidence that 2HG acts as a PHD activator, and increases the 



























Figure 13. Reaction catalyzed by mutant IDH enzymes. 
(A) Reaction catalyzed by wild-type IDH. (B) Reaction catalyzed by mutant IDH. 
 
TET enzymes catalyze the hydroxylation of 5-methylcytosine residues in DNA. 
The hydroxylation of these cytosine residues ultimately results in global DNA 
remodeling. When TET2 is inhibited, it prevents this intermediate step from occurring, 
and affects gene transcription and genome stability. Data also suggests that 2HG 
accumulation inhibits the activity of histone demethylases such as KDM, enzymes that 
regulate patterns of histone methylation at lysine residues, and causes chromatin 
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remodeling [141]. Overall, the inhibition of these dioxygenases results in alterations that 
block the cellular differentiation of neuronal cells and hematopoietic cells, cause 
epigenetic reprogramming, and ultimately lead to tumorigenesis [140-142].  
 
Figure 14. The oncometabolite 2HG inhibits "KG-dependent dioxygenases. 
IDH mutants produce 2HG from NADPH-dependent reduction of !KG. Tumor cells 
expressing mutant IDH1 or IDH2 have high levels of 2HG. 2HG is an oncometabolite 
that inhibits !KG-dependent dioxygenases, alters DNA and histone methylation, and 
causes to epigenetic alterations that ultimately lead to tumorigenesis. 
2.5 Diagnostic and therapeutic targeting of Human IDH mutation 
Quite often IDH mutations converge with other genetic aberrations to contribute 
to the malignant transformation of brain tissue. Gliomas possess different molecular 
signatures: 1p/19q codeletion, MGMT promoter methylation, IDH mutation, and glioma-
specific CIMP, as well as mutations in PTEN, MDM2, EGFR, and TP53. The impact of 
these molecular alterations on patient outcomes and therapy is still being assessed. 
However, as treatment options evolve, and we learn more about the molecular 




molecular biomarkers such as IDH1, in addition to histological grade and subtype, will be 
included in the development of new treatment regimens based on the molecular status of 
the tumor.  
The detection of IDH mutations through the use of a monoclonal antibody that 
recognizes IDH1 R132H protein, is already being utilized as a diagnostic marker in the 
assessment of IDH status in glioma biopsy sections [143]. In the future, the possibility 
also exists that 2HG might be used as a biomarker by clinicians. It can be detected in the 
serum of patients and could serve as a less invasive means to track disease progression or 
recurrence than a biopsy. It could also serve as a means of tracking the effectiveness of a 
new treatment regimen.  
Small molecules that specifically target the enzymatic activity of mutant IDH1 
and IDH2 would also provide a new therapeutic opportunity for drug development. X-ray 
crystallography is a powerful tool that provides detailed three-dimensional information 
about binding pockets. In the past, structure-based drug design (SBDD) has been used 
with some success to find small molecules when the structure of a target is known [144, 
145]. Bristol-Myers Squibb developed Captopril, and it was among the first successes of 
SBDD in the late 70s. The development of HIV inhibitors followed in the early 90s. 
Knowledge of the ATP-binding site of kinases led to the discovery of the cancer 
therapeutics Erlotinib (Tarceva) and Imatinib (Gleevac). Modeling and virtual screening 
of binding sites can assist with drug design by mapping the spatial and physico-chemical 
properties of the binding pocket. More recently, fragment-based drug design is emerging 
as a new screening tool that can lead to the rational design and synthesis of lead 




2.5.1 Protein-Protein Interfaces and Structure-Based Drug Design 
Protein-protein interfaces (PPI) have not been the first choice for drug developers, 
mostly due to the difficulty in targeting them. The incentive for drug discovery teams to 
push the boundary comes from the saturation of established drug discovery targets such 
as protein kinases, nuclear receptors, voltage-gated ion channels, and G protein-coupled 
receptors. PPIs reveal a new and virtually inexhaustible area for drug discovery. The 
success of several drugs that target PPIs demonstrates that they are the next frontier [147, 
148]. In the last few years the inhibitors Navitoclax and Obatoclax have been found to 
target interactions of BCL-1 with the tumor suppressors p53 and MDM2 [149]. 
Additionally, a drug for dry eyes that targets the interaction between lymphocyte 
function-associated antigen-1 and the intercellular adhesion molecule-1 (LFA-1/ICAM) 
has entered Phase III clinical trials. The determination of binding sites that contribute to 
the free energy of interaction has also encouraged the development of tethering methods 
that target such sites. In most cases, structural biology is used to determine the site of the 
PPI, but in some cases mutagenesis experiments also complement and assist in localizing 
the amino acid residues that contribute to the binding energy.  
2.5.2 Classes of Protein-Protein Interactions  
There are two types of protein-protein interactions that result in the formation of 
either obligate, stable complexes, or transient complexes [150]. The latter are the 
consequence of a signaling or activation process, or posttranslational modification and 
involve binding cofactors and substrates. The interface formed by obligate complexes is 
large and hydrophobic, while transient complexes tend to have a more polar surface area 




occur between protein complexes that can be targeted and trapped during these 
conformational changes. Quite often, these interactions occur at a dimer interface as in 
the case of survivin [151, 152]. The binding of cAMP-response-element-binding protein 
(CREB) to CREB-binding protein (CBP) is an example of folding and binding where the 
groove of the kinase inducible interacting domain of CBP accommodates the helices of 
the kinase inducible domain of CREB [153]. The NMR structure gave information about 
the binding interactions between CBP and CREB, and this interface has been disrupted 
by the compound KG-501 [154]. 
2.5.3 Physical characteristics of new PPI sites 
Protein-protein interfaces are often characterized by a large surface area of 1500-
3000 Å2 [155, 156]. Most effective small molecules target a smaller area rather than the 
whole interface. The molecular surface tends to be flatter than a typical active site, and 
has ‘energetic hot spots’ [157]. However, most surfaces have an overrepresentation of 
hydrophobic residues clustered in patches. Van der Waal’s forces, hydrogen bonding and 
charge-charge interactions are the obvious weak electronic interactions observed. The 
compounds that disturb PPI tend to be large and lipophilic, with several aromatic rings 
and fewer rotatable bonds. In addition, these compounds tend to be more rigid than those 
that typically bind active sites. 
2.5.4 Discovering and navigating new PPI landscapes 
Small molecule and fragment-based screening can be successfully used to explore 
the chemical space efficiently [158, 159]. For example, chemical libraries of low affinity 




spectrometry to detect compounds with an active thiol is a method engineered by Wells 
[160]. The limitation of this method is the requirement of engineered cysteines in the 
protein target. A second approach is to dock compounds by conventional fragment based 
screening using libraries [159, 161]. X-ray crystallography can detect even low, 
millimolar binders. Nuclear magnetic resonance (NMR), X-ray crystallography, surface 
plasmon resonance (SPR), thermal shift fluorimetry (TSF), differential scanning 
fluorimetry (DSF), or isothermal calorimetry (ITC) are required to screen and validate 
fragment binding [161]. Although in silico design has its limitations, it can yield valuable 
information about the chemical space. Structure-activity relationships are a source of 
information that can complement data from TSF, DSF, and ITC. Another more creative 
approach, involves the use of porphyrins or proteomimetics such as stapled peptides, or 
helical elements to probe binding interactions.  
2.6 Objectives 
The overall goal of this project was to advance the knowledge of the molecular 
architecture and reaction mechanism of the IDH1 R132H mutant through crystal structure 
determination. We were interested in finding small molecules that inhibit mutant IDH1 to 
suggest possible modifications or medicinal chemistry for the development of cancer 
therapeutics. Our specific aims relating to this project were twofold: we sought to explore 
the mechanisms of action of small molecules that interact with the IDH1 R132H mutant; 
we also used structural biology to observe the binding site of small molecules to the 
IDH1 R132H mutant to map the spatial and biophysical properties, to determine if this 






3.1 General Methods 
3.1.1 High-throughput screen of small molecules 
A High-throughput screen was conducted on a 384 well plate using a subset of the 
ChemBridge Library. Small molecules were selected based on a three-dimensional 
pharmacophore in order to identify !-ketoglutarate mimetics. Forty-eight compounds 
with one or more carboxylic acid groups or derivatives thereof were selected and 
screened for inhibition of IDH1 R132H (Figure 14). From this primary screen, three 
compounds were selected and advanced to a biochemical activity assay. Compound 
concentration was set at 0.133 mM and the assay carried out in the reducing direction 
with 33 mM Tris acetate pH 7.4, 1.3 mM MgCl2, 40 mM NaHCO3, 0.4 mM NADPH, 0.5 
mM !-KG and purified IDH1 R132H (Figure 15). Assay progression was monitored at 
340 nm using a microplate reader (BMG POLARstar Omega).  
3.1.2 Enzymatic inhibition assays with small molecules 
The consumption of NADPH was used to measure the activity of IDH1 R132H in 
the presence of small molecules, as it converted !-ketoglutarate to 2-hydroxyglutarate. 
Small molecules, A07 (ChemBridge, 5662524) and ZAG (XcessBiosciences, IDH-C35), 
(Figure 16) were prepared as 10 mM stocks using DMSO and subsequently diluted to a 
concentration of 0.2 mM in the final reaction volume. The assay was conducted in a 384 




R132H diluted in assay buffer containing 20 mM Tris-Cl pH 7.5, 150 mM NaCl, 10 mM 
MgCl2, 0.200 mM NADPH, 0.05% bovine serum albumin, and 2 mM "-mercaptoethanol 
in a volume of 39 µL, with the addition of 1 µL of 10 mM stock of A07 or 10 mM stock 
ZAG, and incubated for 60 minutes. Additionally, 40 µL control reactions containing 
assay buffer with and buffer without NADPH (20 mM Tris-Cl pH 7.5, 150 mM NaCl, 10 
mM MgCl2, 0.05% bovine serum albumin, and 2 mM "-mercaptoethanol) were prepared 
as outlined above. These reactions with IDH1 R132H alone, A07 alone, and ZAG alone 
were utilized to analyze the absorbance of the compound both in the presence and 
absence of NADPH. Following the addition of 10 µL of 5 mM !KG (the substrate), IDH1 
R132H activity was monitored spectrophotometrically at 340 nm using a microplate 
reader (BMG POLARstar Omega). In order to assess the consumption of IDH1 R132H 
over time, scans were taken before the addition of substrate, and after at 2, 15, 30, 60, 90, 
120, 180, and 240 minutes, in the absence or presence of 0.2 mM A07 or 0.2 mM ZAG. 
3.1.3 Sequence alignment of IDH enzymes 
The amino acid sequences of three eukaryotic species of isocitrate dehydrogenase 
and two human isoforms of IDH were selected for structure-guided sequence alignment. 
The selected protein sequences were aligned using Clustal Omega [162]. The resulting 
figures containing secondary structural elements were generated using the program 




3.2 Methods for structure determination of selenomethionine-replaced IDH1 R132H 
3.2.1 Protein expression and purification  
Full-length Homo sapiens IDH1 was cloned into the pET-22a vector and mutant 
IDH1 R132H was generated using QuickChange site-directed mutagenesis (Stratagene). 
Both plasmids were a generous gift from the laboratory of Dr. Bert Vogelstein (Ludwig 
Center for Cancer Genetics and Therapeutics). Plasmid DNA was used to transform 
bacterial cells and IDH1 R132H was expressed in E. coli B834 (DE3) strain (Novagen) to 
generate the seleno-methionine replaced protein. Cells were grown overnight at 37°C in 
60 mL M9 media supplemented with 5% LB media and 100 µg/mL ampicillin. Cells 
were harvested at 6000 rpm in a Sorvall GSA rotor at 4°C, and resuspended in M9 media 
containing 100 µg/mL seleno-L-methionine (Sigma) and 100 µg/mL ampicillin. After 
growth to 0.6 at A600, expression was induced with 1 mM "-D-1-thiogalactopyranoside 
(IPTG) and growth continued overnight at 25°C. Cells were harvested by centrifugation, 
washed with 20 mM Tris-Cl pH 7.4, 500 mM NaCl, 10 mM imidazole, 10% glycerol, 
0.1% Triton X-100, 5 mM "-mercaptoethanol, pelleted, and stored at %80°C.  
After thawing, cells were resuspended in lysis buffer: 20 mM Tris-Cl pH 7.4, 500 
mM NaCl, 10 mM imidazole, 10% glycerol, 0.1% Triton X-100, and 5 mM "-
mercaptoethanol, with one dissolved Complete EDTA-free protease inhibitor tablet 
(Roche), and lysed using microfluidization. Cellular debris was pelleted and removed by 
centrifugation on a Sorvall GSA rotor for 30 minutes at 12,000 rpm. The lysate was 
filtered through a 0.2 µm filter and loaded onto a HisTrap HP 5 mL column (GE 
Healthcare) pre-equilibrated with buffer containing 20 mM Tris-Cl pH 7.4, 500 mM 




were washed for 20 column volumes with this buffer. Target protein was eluted by an 
imidazole gradient with 10-50% of buffer containing 20 mM Tris-Cl pH 7.4, 500 mM 
NaCl, 500 mM imidazole, 10% glycerol, 5 mM "-mercaptoethanol (Figure 20). Fractions 
containing protein were pooled and dialyzed using 10 kD MWCO membrane (Pierce 
Snakeskin) against an excess of buffer containing 20 mM Tris-Cl pH 8.5, 150 mM NaCl, 
and 5 mM "-mercaptoethanol, at 4°C with agitation overnight. The following morning, 
protein was dialyzed twice against 2L of binding buffer (20 mM Tris-Cl pH 8.5, 50 mM 
NaCl, and 5 mM "-mercaptoethanol) for a total of 4 hours. The dialysis buffer was 
filtered through a 0.2 µm filter and used as the equilibration and binding buffer for the 
next step of purification. The protein was further purified over a Source Q column (GE 
Healthcare), using anion exchange chromatography. The column was pre-equilibrated 
with buffer A (20 mM Tris-Cl pH 8.5, 50 mM NaCl, and 5 mM "-mercaptoethanol) 
before applying protein sample over the column. Unbound proteins were washed with 4 
column volumes of binding buffer, and target protein was eluted with a gradient to 50% 
of buffer B (20 mM Tris-Cl pH 8.5, 1 M NaCl, and 5 mM "-mercaptoethanol) over 20 
column volumes (Figure 21). Fractions of protein containing & 95% purity were collected 
and dialyzed against an excess of buffer containing 20 mM Tris-Cl pH 8.0, 150 mM 
NaCl, and 5 mM "-mercaptoethanol. Target protein was concentrated to 15-20 mg/mL, 
and stored at %80 °C. All chromatographic separations were performed on AKTA Basic 
Fast Protein Liquid Chromatography (FPLC) system. 
3.2.2 Crystallization of selenomethionine-replaced IDH1 R132H 
Crystallization screening of Se-Met IDH1 R132H was performed using incomplete 




with a reservoir of 500 µL. Protein complexes were co-crystallized from solutions 
consisting of 15-20 mg/mL Se-Met IDH1 R132H mixed with either 1 mM !KG or 1 mM 
ICT. Drops containing 1 µL of protein and 1 µL of reservoir solution were equilibrated 
against a reservoir containing 0.1 M Tris-Cl pH 8.0, 0.2 M ammonium sulfate, and 25.0 - 
27.5% PEG 3350 (w/v). Diffraction quality crystals were obtained in 2 weeks at 20°C. 
Crystals were soaked with 0.02 mM A07 for 60 min and frozen using 2 M lithium sulfate 
as a cryoprotectant.  
3.2.3 MAD data collection and processing 
The X-ray diffraction data for selenomethionine-derivatized IDH1 R132H crystals 
and selenomethionine-derivatized IDH1 R132H crystals in complex with inhibitor A07 
were collected at beam line X6A of the National Synchotron Light Source (NSLS) at 
Brookhaven National Laboratory, at the selenium peak wavelength of 0.9793 Å. The 
crystals diffracted to a resolution of 2.1 Å in the absence of inhibitor and 3.0 Å in the 
presence of A07 respectively (Table 4). Data were processed with HKL2000 [164] . 
3.2.4 Structure determination, phase calculation, and refinement 
Phases were determined by multiple wavelength anomalous diffraction (MAD) 
using data collected on selenomethionine-derivatized crystals of IDH1 R132H. The 
SOLVE/RESOLVE software suite was used to determine the positions of the 
anomalously diffracting selenium atoms and for initial model building [165-168]. The 
structure of the selenomethionine-derivatized IDH1 R132H crystals, in complex with 
ICT-NADP and A07, were determined by Fourier synthesis using the coordinates of the 




rounds of model rebuilding were carried out with the program Coot [169]. The initial 
model was refined using PHENIX [170, 171] or REFMAC5 [172] in the CCP4i suite. A 
free R factor set of 5 % of randomly chosen reflections was kept during the refinement 
for cross validation purposes. Figures of the structures were prepared using the program 
Pymol [173]. Refinement statistics for both data sets are given in Table 4. 
3.3 Methods for structure determination of IDH1 R132H  
3.3.1 Protein expression and purification 
Plasmids containing full-length H. sapiens IDH1 and IDH1 R132H were a gift 
from the laboratory of Dr. Bert Vogelstien. Plasmid DNA of IDH1 R132H was used to 
transform BL21 (DE3) cells (Novagen). Eight liters of bacterial cells were grown at 37°C 
in LB medium supplemented with 100 µg/mL ampicillin to 0.7 at A600. Protein 
expression was induced with the addition of 1 mM IPTG and growth was continued at 
18°C overnight. Cells were harvested by centrifugation and washed with 20 mM Tris-Cl 
pH 7.4, 500 mM NaCl, 10 mM imidazole, 10% glycerol, 0.1% Triton X-100, and 5 mM 
"-mercaptoethanol. Following this wash step, cells were subsequently pelleted and stored 
at %80 °C. 
Cells were resuspended in lysis buffer containing 20 mM Tris-Cl pH 7.4, 500 mM 
NaCl, 10 mM imidazole, 10% glycerol, 0.1% Triton X-100, 5 mM "-mercaptoethanol, 
with one dissolved Complete EDTA-free protease inhibitor tablet (Roche) after thawing. 
Following lysis via microfluidization, cellular debris was pelleted and removed by 
centrifugation in a GSA rotor for 30 minutes at 12,000 rpm. The lysate was filtered 
through a 0.2 µm filter and loaded onto a HisTrap HP 5 mL column (GE Healthcare) pre-




10% glycerol, and 5 mM "-mercaptoethanol). Unbound proteins were washed for 20 
column volumes with this buffer. An imidazole gradient was used to elute target protein 
with 10-50% of buffer B (20 mM Tris-Cl pH 7.4, 500 mM NaCl, 500 mM imidazole, 
10% glycerol, and 5 mM "-mercaptoethanol) (Figure 22). Fractions containing protein 
were pooled and dialyzed using 10 kD MWCO membrane (Pierce Snakeskin) against an 
excess of buffer containing 20 mM Tris-Cl pH 8.5, 150 mM NaCl, and 5 mM "-
mercaptoethanol, at 4°C with agitation overnight. The following morning, protein was 
dialyzed twice against 2L of binding buffer (20 mM Tris-Cl pH 8.5, 50 mM NaCl, and 5 
mM "-mercaptoethanol), for a total of 5 hours. The dialysis buffer was filtered through a 
0.2 µm filter and used as the equilibration and binding buffer for the next step of 
purification. The protein was further purified over a Source Q column (GE Healthcare), 
using anion exchange chromatography. The column was pre-equilibrated with buffer A 
(20 mM Tris-Cl pH 8.5, 50 mM NaCl, and 5 mM "-mercaptoethanol) before applying 
protein sample over the column. Unbound proteins were washed with 4 column volumes 
of binding buffer and target protein was eluted with a gradient to 100% of buffer B (20 
mM Tris-Cl pH 8.5, 1 M NaCl, and 5 mM "-mercaptoethanol) over 20 column volumes 
(Figure 23). Fractions of target protein containing & 95% purity were collected and 
dialyzed against an excess of buffer containing 20 mM Tris-Cl pH 8.0, 150 mM NaCl, 
and 5 mM "-mercaptoethanol. Protein was concentrated to 15-20 mg/mL, and stored at 
%80 °C. 
3.3.2 Crystallization of IDH1 R132H 
The crystallization screening of IDH1 R132H was performed as described for 




optimized using hanging drop vapor diffusion, with diffraction quality crystals obtained 
in 2 weeks at 20°C with drops containing 1 µL of protein and 1 µL of reservoir solution, 
equilibrated against a reservoir of 100 mM Tris-Cl pH 8.0, 200 mM ammonium sulfate 
and 25.0 - 27.5% PEG 3350 (w/v). Protein complexes were co-crystallized from solutions 
consisting of 15-20 mg/mL IDH1 R132H mixed with 1 mM ICT (Figure 24). Crystals 
were soaked with 0.02 mM ZAG for 60 min and frozen using 2 M lithium sulfate as a 
cryoprotectant.  
3.3.3 Data collection and processing  
Data for IDH1 R132H crystals in complex with ZAG were collected at LRL-CAT 
beam line 31A of the Advanced Photon Source (APS). The crystals diffracted to a 
resolution of 3.3 Å in the presence of ZAG. Indexing and data reduction for crystals was 
carried out using HKL2000 [164].  
3.3.4 Structure determination, phase calculation, and refinement  
The structure of IDH1 R132H crystals in complex with ICT-NADP and ZAG, were 
determined by Fourier synthesis using the coordinates of the selenomethionine-
derivatized IDH1 model. To summarize, Coot was used for iterative rounds of rebuilding 
[169], with further refinement performed with REFMAC5 [172]. A free R factor set of 
5% of randomly chosen reflections was kept during the refinement for cross validation 
purposes. Pymol was used to generate figures of the structures [173] Refinement statistics 
for this data set are given in Table 4. 
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Figure 15. High-throughput screen based on three-dimensional pharmacophore. 
An initial screen was conducted with a subset of small molecules from the ChemBridge 
Library. Three small molecules were selected from this initial screen and advanced. 
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Figure 16. Secondary small molecule screen with "KG mimetics. 
Panel displays three small molecules identified from initial high-throughput screen and 
advanced to the secondary screen. All three compounds had an inhibitory effect on 
mutant IDH1. The legend lists the concentrations (µM) used for the small molecules in 
the screen with the absorbance on the y-axis and time in minutes on the x-axis.
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Figure 17. Chemical structures of small molecules used in studies. 
(A) A07 and (B) ZAG were used in the NADPH depletion assays as well as in the 
structural determination of IDH1 R132H. A07 was identified during a high-throughput 
screen using a subset from a ChemBridge Library and ZAG is an IDH1 inhibitor 
identified by Agios Pharmaceuticals. 
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Figure 18. Ni2+-affinity chromatography of Se-Met replaced IDH1 R132H. 
(A) Chromatogram of purification. Blue line denotes absorbance at 280 nm in 
milliabsorbance units and green line represents gradient of elution buffer with 
concentration listed on right axis. Pink line denotes sample injection. (B) SDS-PAGE gel 
of purification stained with Coomassie blue stain. M refers to molecular weight ladder in 
kilodaltons. Relevant fractions are shown: S refers to soluble lysate, FT to unbound 
proteins or “flow through,” also fractions from 3rd peak in blue trace are shown. 
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Figure 19. Anion exchange chromatography of Se-Met replaced IDH1 R132H. 
(A) Chromatogram of purification. Blue line denotes absorbance at 280 nm in 
milliabsorbance units and green line represents gradient of buffer used for elution with 
concentration. Pink line denotes sample injection. (B) SDS-PAGE gel of purification 
stained with Coomassie blue stain. M refers to molecular weight ladder in kilodaltons and 
L to sample loaded onto column. Fractions corresponding to peak are shown. 
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Figure 20. Ni2+-affinity chromatography of IDH1 R132H. 
(A) Chromatogram of purification. Blue line absorbance at 280 nm in milliabsorbance 
units and green line represents gradient of buffer used for elution. Pink line denotes 
sample injection. (B) SDS-PAGE gel of purification stained with Coomassie blue stain. 
M refers to molecular weight ladder in kilodaltons. P to insoluble pellet, S refers to 
soluble lysate, FT to unbound proteins or “flow through,” fractions from 3rd peak in blue 





Figure 21. Anion exchange chromatography of IDH1 R132H. 
(A) Chromatogram of purification. Blue line denotes absorbance at 280 nm in 
milliabsorbance units and green line represents gradient of buffer used for elution with 
concentration listed on right axis. Pink line denotes sample injection. (B) SDS-PAGE gel 
of purification stained with Coomassie blue stain. M refers to molecular weight ladder 





Figure 22. Crystal complex formed by IDH1 R132H, NADP+, and ICT. 
Crystals of IDH1 R132H were grown by hanging drop vapor diffusion. NADP+co-
purified with enzyme. Protein complexes were co-crystallized from solutions of protein 







4. Mechanistic Insights from Structure Determination of IDH1 
R132H 
 
4.1 Activity of small molecules against IDH1 R132H  
Three out of 48 selected compounds displayed IDH1 R132H inhibition in the 
primary screen at a concentration of 133 uM. Subsequently, these compounds were 
retested in oxidizing and reducing assays with ICT and NADP+ vs. !KG and NADPH 
respectively, in a dose range from 8.3 uM to 133 uM. Three compounds inhibited IDH 
R132H in a dose dependent fashion in the reducing assay modality but no inhibition of 
IDH1 R132H was observed in the oxidative assay mode at any concentration. These 
compounds were advanced to a secondary screen and one compound, 5662524, (from this 
point on referred to as A07) was selected for biochemical assays in addition to ZAG. 
ZAG was identified from high-throughput screens conducted by Agios Pharmaceuticals. 
It has been shown to be an effective inhibitor against IDH1 R132H and reduces 
production of the oncometabolite 2HG in a glioma cell line [174]. 
Enzymatic inhibition assays were conducted with A07 and ZAG to further assess 
their inhibitory effects against IDH1 R132H. The consumption of NADPH was used to 
measure the activity of IDH1 R132H in the absence and presence of small molecules, as 
it converted !-ketoglutarate to 2-hydroxyglutarate. Substrate was added and all reactions 
were allowed to proceed for 4 hours. Reactions were monitored spectrophotometrically at 




consumed after 90 minutes in control reactions. However, in the presence of either 0.2 
mM A07 (Figure 23) or 0.2 mM ZAG (Figure 24), IDH1 R132H was inhibited and the 
absorbance corresponding to the NADPH signal remained above zero. ZAG was more 
effective at inhibiting IDH1 R132H and blocking NADPH consumption than was A07. 
A07 limited the enzymatic activity of IDH1 R132H and reduced the consumption of 
NADPH. In contrast, the inhibition was more pronounced for reactions containing ZAG, 
the NADPH signal remained constant over the time course and there was virtually no 
change in the absorbance (Figure 24). 
4.2 Structural insights from IDH1 R132H  
4.2.1 Overall structural features 
IDH1 R132H forms a homodimer in the asymmetric unit and belongs to the space 
group P43212 (Table 4). Each monomer consists of 414 amino acids folded into three 
domains: large domain, small domain, and the clasp domain (Figure 25). Residues 1-103 
and 286-414 make up the large domain, which has a Rossman fold typical of most 
oxidoreductases, while residues 104-136 and 186-285 make up the small domain which 
forms an !/" sandwich (Figure 26). A total of two-stacked anti-parallel "-sheets 
consisting of residues 137-185, form the clasp domain, which interlocks the two 
monomers. The small and clasp domains are the primary site of the interaction of the 
swapped domains. The region of the active site in both monomers is similar and yet not 
identical. As a reflection of the asymmetry of the monomers in the dimer, an RMSD of 
1.42 Å is observed for 396 C! atom pairs. The semi-open homodimer buries 2309 Å2 




tighter interaction between monomers and the formation of a more compact dimer [175, 
176].  
Each monomer contains an active site cleft formed by the large and small domains. 
In the structures of IDH1 R132H-ICT-NADP+ in the semi-open conformation, a molecule 
of NADP+ binds at the NADP-binding site in each subunit, with isocitrate binding at 3.9 
Å from the nicotinamide moiety and forming hydrogen bonds with amino acid residues 
of the large domain. Interestingly, NADP+ is bound to the purified enzyme as reported for 
wild type IDH1, although none was added at the crystallization step. Similarly, in 
structures of IDH1 R132H in complex with !KG and NADP+, a molecule of NADP+ 
binds within each subunit at the NADP-binding site, and in this structure !KG is 3.8 Å 
from the nicotinamide moiety of NADP+.  
4.2.2 NADP+ binds the semi-open conformation 
The binding site of NADP+ is formed by amino acid residues from the large domain 
of IDH1 R132H. The residues T77, H309, and G310 all form hydrogen bonds with 
NADP+, in structures of IDH1 R132H in complex with !KG (Figure 27). In the structure 
of IDH1 R132H-ICT-NADP+ the residues T75, N96 and E306 all form hydrogen bonds 
with the nicotinamide moiety of NADP+, while the phosphates are recognized by the 
main chains of G310, T311, V312, and the side chain of R314. The residues T77, R82 
and T311 recognize the ribose, while the adenine moiety of NADP+ forms hydrogen 
bonds with N328 (Figure 28). Interestingly, a phosphate is consistently observed bound 
to R314 in all three structures. This recognition site differs from that of the closed 




residues of one subunit and D253, N257 and K260 from the other. However, in both of 
our structures the adenine is only recognized by the N328 residue of one subunit.  
4.2.3 Both !-ketoglutarate and isocitrate bind the semi-open conformation 
In our structure, the !-ketoglutarate forms hydrogen bonds with water molecules, 
S94, R100, and is 3.8 Å from the nicotinamide moiety of NADP+ in this conformation 
(Figure 29). The H132 that replaces an arginine residue at this position does not form 
hydrogen bonds with other residues in the active site. It is 7.9 Å away from the substrate. 
In the structure of IDH1 R132H-!KG-NADP-Ca, in the closed catalytically active 
conformation, the !KG interacts with T77, S94, R100, D275, from one subunit and T214 
and D252 from the other subunit [18]. Both Y139 and K212 adopt different positions in 
the active site of our semi-open structure compared to those observed in the closed 
conformation.  
In our structure of IDH1 R132H-ICT-NADP+, the isocitrate is within hydrogen 
bonding distance to R100, S94, and T77, which differs from the isocitrate binding site in 
the closed conformation (Figure 30). This differs from the quaternary structure of the 
IDH1-NADP-ICT-Ca2+ (PDB code 1T0L, [18]), where R132 is within hydrogen-bonding 
distance to isocitrate and interacts with it. In that conformation, isocitrate also interacts 
with R109, R132, Y139 and D275 of one subunit, and K212, T214, and D252 of the 
other subunit. In this structure H132 is within 8.0 Å of the isocitrate.  
4.2.4 Active site of semi-open conformation differs from closed conformation 
Based upon substrate binding and release, IDHs undergo conformational changes 




conformation (PDB code 3INM, [43]) the large domain rotates 30° relative to the small 
and clasp domains (Figure 31). There are notable differences between the active site 
observed in the closed conformation in comparison to the semi-open conformation. The 
active site of the closed conformation is more compact. An RMSD of 4.71 Å is observed 
between the semi-open and the closed conformations (Figure 31). 
In the wild type enzyme, residues 132-141 form a hinge that moves upon ICT 
binding, while residues 271-286 form a loop or ‘regulatory segment’ that protrudes into 
the ICT binding site but shifts substantially during catalysis [18]. However, in our 
structures, residues 271-286 of monomer A form a helix that is less flexible than the 
regulatory segment formed in the closed catalytically active conformation, and the 
equivalent loop or helix is missing in monomer B. Typically, a salt bridge is formed 
between R132 and the oxygen atom of D275 in subunit A; while in subunit B, R132 
forms a salt bridge with the oxygen of D279. This aspartate residue, D279, also forms 
hydrogen bonds with the divalent ion allowing it to participate in catalysis. It is plausible 
that D252, D275, or D279 may be responsible for the initial proton abstraction from the 
hydroxyl of isocitrate, allowing the transfer of the hydride anion from the C2 of ICT to 
the C4 of the nicotinamide ring of NADP+. The aspartate residues are also responsible for 
coordinating the divalent metal ion.  
The arginine residues, R100, R109, and R132, are thought to promote proton 
abstraction by lowering the pKA of the metal-bound ICT. However, in our structures of 
mutant IDH1 in complex with either !KG or isocitrate, a histidine residue (H132) now 
replaces the arginine residue (R132) that would typically reside in this position so that 




Additionally, Y139 is not ordered, and cannot be traced from the binding site of the 
isocitrate in our structures of the semi-open conformation, but it is present in the active 
site of the closed conformation (Figure 32).  
4.2.5 Small molecules bind mutant IDH1 at the dimer interface  
To determine the binding site of the small molecules A07 and ZAG in IDH1 
R132H, we determined the structure of IDH1 R132H-ICT-NADP-A07 by x-ray 
crystallography with data to 3.0 Å (Figure 33) and that of IDH1 R132H-ICT-NADP-ZAG 
to 3.3 Å (Figure 34). In both structures, the small molecules bind at the dimer interface of 
the semi-open IDH1 R132H (Figure 35). The complex structures IDH1 R132H-ICT-
NADP-A07 and IDH1 R132H-ICT-NADP-ZAG possess great similarity to other semi-
open structures (PDB code 3MAP, [177]) as shown by small RMSD of 1.2 Å between the 
C! atom pairs upon superposition of monomer A. The allosteric binding site of A07 is 
between helix 252-259, loop 110-130 of monomer A, and opposite to the face of NADP 
of monomer B, 8 Å from the ribose and 26.8 Å from monomer A. The temperature factor 
of the binding site area is higher than that of the other portions of the structure, 
suggesting that the interface participates in the conformational changes required for 
catalysis. Both small molecules are approximately 8.6 Å away from IDH1 R132H. There 
was no binding observed of the small molecules to the wild type enzyme. These results 
suggest that both inhibitors bind in a pre-formed cavity that is not present in the closed 
structure (Figures 36 and 37). 
The allosteric site observed in the inactive semi-open conformation of IDH1 
R132H is asymmetric and locks the enzyme in a conformation that prevents the 




(Figure 35). In this conformation, the large domain is separated from the small and 
catalytic domain. Until now, only structures of IDH2 were determined in complex with 
inhibitors that displayed binding at the interface of the homodimer. This work shows that 
the preformed cavity allows for binding of IDH1 to allosteric inhibitors as well.  
These structures confirm the dominant inhibition of the IDH1 mutation in the semi-
open form and demonstrates that the dimer interface of IDH1 is druggable. It has a pre-
defined pocket that participates in catalysis as it cycles between the open and closed 
conformations. Both compounds can be described as stabilizing and interfacial [161]. 
ZAG and AO7 inhibit the protein-protein interface required for catalytic activity and 
stabilize the semi-open conformation that precludes the conformation necessary for 
catalysis. As other ‘stabilizers’, they are also allosteric, binding at a site other than the 
active site. The inhibitors are interfacial and are juxtaposed to the interface using a grove 
present in one of the monomers. Using a combination of high throughput screening, 
inhibition assays, and structural biology, we identified a site of protein-protein interaction 
that provides an opportunity for selectivity different from the over-targeted sites of 
isocitrate and !-ketoglutarate. This work is yet another example of how structural biology 
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Data Collection Statistics    
X-ray Source BNL-X6A BNL-X6A APS-31  
Wavelength (Å) 0.9793  0.9793 1.07  
Resolution (Å)  










640,895 766,097 730,587  
Unique Reflections 61,099 19,076 16,176  
I/' 36.3 (3.5) 14.3 (4.1) 20.3 (6.8)  
Completeness (%) 99.7 87.7(86.0) 99.3(100)  
Rsymm (%) 9.5 12.0 11.0  
Refinement    
Rcryst (%) 19.9 21.9 19.7  
Rfree 23.5 30.8 27.6 
 
 
Monomer in ASU 2 2 2  
Protein atoms 7121 6979 6318  
Water molecules 781 74 73  
RMSD    
 
    
Bond length (Å) 0.015 0.013 0.019  
Angle (°) 1.61 1.63 1.77  
B-factor (Å2)     
Protein 29.0 51.0 33.6 
Ligand 29.0 68.0 69.6 
Water molecules 33.4 30.5 22.6 
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Figure 23. A07 blocks consumption of NADPH by IDH1 R132H. 
(A) NADPH depletion assay performed in the absence of A07. (B) NADPH depletion 
assay in the presence of A07. Assays were followed spectrophotometrically at 340 nm to 
observe differences in the absorbance between reactions containing A07 and those 
without. The absorbance decreases as the reaction proceeds but, it does not drop to zero. 
This indicates that A07 limits the enzymatic activity of IDH1 R132H and blocks the 
consumption of NADPH. Scans were taken at the time points listed to the right in the 
legend.  
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Figure 24. ZAG greatly reduces consumption of NADPH by IDH1 R132H. 
(A) NADPH depletion assay performed in the absence of ZAG. (B) NADPH depletion 
assay in the presence of ZAG. Assays were followed spectrophotometrically at 340 nm to 
observe differences in the absorbance between reactions containing ZAG and those 
without. The absorbance remained constant as the reaction proceeded, indicating that 
ZAG inhibits IDH1 R132H and prevents the consumption of NADPH. Scans were taken 
at the time points listed to the right in the legend. 
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Figure 25. IDH1 R132H is an asymmetric homodimer. 
Ribbon diagram displaying the overall structure of mutant IDH1 enzyme with individual 
chains shown in two different shades of blue. There is an active site present in each 
monomer. Within each active site, NADP+  and !-ketoglutarate are colored by chain and 
shown as sticks. 
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Figure 26. Monomers of IDH1 R132H have three domains. 
(A) Ribbon diagram displaying overall structure of homodimer with both monomers
shown. (B) Ribbon diagram depicting monomer A. Domains are colored in the following 
manner: the clasp domain is shown in magenta; the small domain is shown in gray; and 
the large domain is shown in blue. The clasp domain folds as two stacked anti-parallel "-
sheets that interlock the two monomers. The small domain forms an !/" sandwich and the 








Figure 27. NADP+ binds the semi-open conformation of IDH1 R132H. 
A ribbon diagram displaying the NADP+ binding site. NADP+ interacts with amino acid 
residues of the large domain and the hydrogen-bonding pattern is displayed with gray 
dash marks. NADP+ and amino acid residues are shown as sticks with carbons colored 












Figure 28. IDH1 R132H forms a complex with ICT, NADP+, and A07. 
Ribbon diagram of the active site showing the relationship between A07, isocitrate, and 
NADP+. The binding site of NADP+ is shown with interacting residues from the large 
domain. The hydrogen-bonding pattern is displayed with gray dash marks. Isocitrate, 
NADP+, and amino acid residues are all displayed as sticks with carbons colored 
according to chain. Water molecules are displayed as red spheres and individual chains 
are shown in green and yellow. 
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Figure 29. "-ketoglutarate binds semi-open conformation of IDH1 R132H. 
Ribbon diagram displaying close-up of the active site showing the relationship between 
!-ketoglutarate and NADP+ with individual chains shown in blue. The amino acid 
residues, !-ketoglutarate, and NADP+, are all displayed as sticks with carbons colored 
according to chain and oxygen atoms shown in red. The hydrogen-bonding pattern is 
shown with gray dash marks and water molecules are displayed as red spheres. 
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Figure 30. Isocitrate binds semi-open conformation of IDH1 R132H. 
Close-up of the active site showing the relationship between A07, isocitrate and NADP+
with individual chains shown in green and yellow. Isocitrate stacks over the nicotinamide 
moiety of the NADP+. Isocitrate, NADP+, and amino acid residues displayed as sticks 




Figure 31. The active site of the closed conformation is more compact. 
(A) Ribbon diagram of IDH1 R132H in the semi-open conformation. The clasp domain is 
displayed in two shades of pink, the small domain colored in two shades of gray, and the 
large domain is shown in two shades of blue. (B) Molecular surface representation of 
IDH1 R132H in semi-open conformation with domains colored as outlined in (B). (C) 
Ribbon diagram of IDH1 R132H in the closed conformation (PDB id: 3INM) with !-
ketoglutarate and NADP+ in the active site. The clasp domain is displayed in two shades 
of pink, the small domain is colored in two shades of gray and the large domain is shown 
in either blue or lilac. Within the rectangle, note the appearance of two helices present in 
the closed conformation that are not present in the semi-open conformation. The large 
domain rotates 30° relative to the small domain. (D) Molecular surface representation of 
closed conformation (PDB id: 3INM) with domains colored as outlined in (C). 
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Figure 32. Active site of semi-open conformation differs from closed. 
Ribbon diagram of the active site of the closed conformation superimposed over the 
active site of the semi-open conformation. The closed conformation (PDB id 3INM) is 
displayed in purple while the semi-open conformation is shown in blue. Residues from 
the active site of the closed conformation are colored in purple according to chain and 
include residues important for catalysis. NADP+ and !-ketoglutarate from the closed 
conformation are displayed in purple with carbons colored according to respective chain. 
Note that NADP+ and !-ketoglutarate have shifted position in the semi-open 
conformation. Both are displayed in blue with carbons colored according to chain.  
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Figure 33. A07 binds mutant IDH1 at allosteric site. 
(A) Molecular surface representation of the asymmetric homodimer of IDH1 R132H with 
individual monomers shown in green and yellow. A single molecule of A07 binds at the 
interface between the two dimers. (B) Ribbon diagram with close-up of binding sites of 
isocitrate, A07 with electron density map, and NADP+. A07, isocitrate, and NADP all 
shown as sticks with carbons colored according to their respective chain.  
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Figure 34. ZAG binds mutant IDH1 at allosteric site. 
Ribbon diagram with close-up of isocitrate, ZAG, and NADP+, displaying the allosteric 
site of binding. ZAG is shown in purple with an electron density map. NADP+, ZAG, and 
isocitrate are all shown as sticks with carbons colored according to their respective chain.  
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Figure 35. Small molecules bind at dimer interface of IDH1 R132H. 
The binding site of A07 is superimposed over the binding site of ZAG. Both small 
molecules bind at the dimer interface. A07 is colored in green with individual chains 
shown in green and yellow ribbons. ZAG is colored in purple with respective chains 
displayed as cyan and purple ribbons. NADP+ and isocitrate are colored according to the 
color of each individual chain.  
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Figure 36. A07 binds mutant IDH1 in a pre-formed cavity. 
A molecular surface representation of the dimer interface colored according to the 
electrostatic potential of the surrounding area. A07 binds in a pre-formed cavity and is 
displayed in green and shown as sticks. NADP+, is shown with carbons in yellow and
isocitrate is displayed with carbons in yellow, both are shown as sticks. Blue shading is 
for positive residues while red coloring is for negative residues. 
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Figure 37. ZAG binds mutant IDH1 in a pre-formed cavity. 
A molecular surface representation of the dimer interface colored according to the 
electrostatic potential of the surrounding area. ZAG is shown in teal and binds in a pre-





5. Appendix I: Overview of the CREB Coactivator Complex  
 
5.1 Introduction 
Glucose is the main nutrient fuel of most organisms and is the sole energy source in 
some mammalian tissues and cells. The liver maintains blood glucose levels within a 
narrow range through the opposing actions of insulin and glucagon. In the fasting state, 
glucagon prevents hypoglycemia by stimulating glycogenolysis during the acute response 
and increasing gluconeogenesis during the chronic response. Postprandially, insulin 
suppresses both hepatic glycogenolysis and gluconeogenesis, thereby preventing 
hyperglycemia [178, 179].  
Inappropriate glucose production is the major cause of the fasting hyperglycemia 
observed in individuals with type 2 diabetes mellitus (T2DM). Elevated glucagon levels 
together with impaired insulin signaling result in hyperglycemia and subsequent T2DM 
[180, 181]. Glucagon is considered a major etiological factor that worsens blood glucose 
control in patients with diabetes. Glucagon, acting through a G-protein coupled receptor, 
promotes the formation of a nuclear coactivator complex involved in the transcriptional 
regulation of hepatic glucose production. This complex consists of one transcription 
factor, cAMP response element binding protein (CREB), and two coactivators, CREB 
binding protein (CBP), and Transducer of Regulated CREB activity 2 (TORC2). 
Together, these proteins form the CREB coactivator complex (CREB/CBP/TORC2) 
[182, 183]. Insulin signaling results in the dissociation of the coactivator complex [182]. 
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CREB belongs to the basic leucine zipper (bZIP) superfamily of transcription 
factors. It is homodimeric and possesses the following motifs: Q1 domain, kinase 
inducible domain (KID), Q2 domain, basic region/leucine zipper (bZIP) domain (Figure
38). The Q1 and Q2 domains are hydrophobic and glutamine-rich. Both of these domains 
interact with components of the basal transcription machinery and have demonstrated 
constitutive activation in binding studies with cultured cells [184, 185]. The KID domain
is the region through which CREB interacts with CBP/p300, and includes a protein 
kinase A (PKA) phosphorylation site, as well as potential sites for other kinases [184, 
186]. The bZIP domain is located towards the carboxy terminal, and the basic region 
mediates DNA binding, while the leucine zipper domain facilitates CREB dimerization
[187, 188]. Within this family, CREB shares a high degree of similarity to the cAMP 
response element modulator (CREM) and the activating transcription factor 1 (ATF-1). 
These closely related proteins (Figure 39) comprise a subfamily referred to as the “CREB 
Family” of transcription factors [189-192]. 
 
Figure 38. Domain architecture of CREB. 
The gray boxes represent Q1 and Q2. These are glutamine-rich domains and are also 
referred to as constitutive activation domains. The kinase inducible domain (KID) is 
displayed in red and contains a PKA phosphorylation site as well as other potential 
phosphorylation sites. The basic region/leucine zipper (bZIP) domain is shown in purple. 
The basic region mediates DNA binding, while the leucine zipper facilitates dimerization. 
CREB is activated in response to many different stimuli and the putative list of 




implicated in learning and memory pathways, as well as growth-factor-dependent cell 
survival, in addition to signaling cascades involved in glucose homeostasis. It binds cis-
regulatory elements, also called cAMP response elements (CRE), located within the 
promoters of several different genes [193]. These CRE sites contain the palindromic 
consensus nucleotide sequence TGACGTCA [193, 194], although in some genes this  
 
Figure 39. The bZIP family of proteins possess high sequence similarity. 
CREB and CREM function as activators or repressors of transcription. They bind CRE 
sites located within gene promoters with high affinity and also form a subfamily which 
includes ATF-1. Conserved residues are displayed in blue and open circles denote deleted 
portions of the CREM construct used in our studies. Secondary structural elements for 





motif is only present as a half site, CGTCA [195, 196]. There are two distinct classes of 
proteins known to mediate transcription of gluconeogenic genes by binding CREB: 
CBP/p300 family of transcriptional coactivators, and the TORC family of proteins. The 
phosphorylation of CREB is essential for cAMP-mediated activation of gene 
transcription and augments its activity by causing the recruitment of transcriptional 
coactivators such as CBP/p300 [197].  
CBP and the paralogue p300 possess intrinsic histone acetyl transferase (HAT) 
activity, which allows them to modify histones and remodel chromatin. In this way, these 
coactivators can switch on transcription by making target gene promoters more accessible 
[198]. CBP/p300 have also been shown to be essential cofactors for several components 
of the basal transcriptional machinery [199, 200]. They play a critical role in the 
expression of a number of endocrine target genes and are closely related. Gene dosage of 
CBP/p300 is critical during development and homozygous CBP and p300 null mice are 
not viable [201]. CBP was first identified and characterized through its binding 
interactions with the KID of CREB [202]. Domain organization is as follows: nuclear 
receptor interacting domain (NR); cysteine/histidine rich region 1 (C/H1); kinase-
inducible domain interacting domain (KIX); bromodomain (BROMO) binds acetylated 
lysine residues; histone acetyltransferase domain (HAT); cysteine/histidine rich region 3 
(C/H3) containing both zinc finger and transcriptional-adaptor zinc finger (TAZ) domains 
(Figure 40). The NR is the domain that interacts with nuclear hormone receptors. The 
C/H1 and C/H3 are also referred to as TAZ1 and TAZ2 domains. They contain cysteine 
residues that participate in zinc-finger binding [203]. The KIX is the domain through 
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Figure 40. Domain architecture of the coactivators CBP and p300. 
The nuclear receptor interacting domain (NR) can bind and interact with nuclear hormone 
receptors and is displayed in purple. The C/H1 (cysteine/histidine rich region 1) and 
C/H3 (cysteine/histidine rich region 3), contain transcriptional-adaptor zinc finger and 
zinc finger domains and are shown in gray. The kinase-inducible domain interacting 
domain (KIX) is the domain that interacts with CREB and is displayed in red. The 
bromodomain (BROMO) binds acetylated lysine residues and is shown in black. The 
histone acetyltransferase domain (HAT) is shown in green and catalyzes acetylation of 
histone proteins. 
which CBP binds CREB, and it also serves as a scaffold or docking site for other 
transcription factors [204]. The bromodomain binds acetylated lysine residues and it 
enhances histone acetylation and promoter binding [205], while the HAT domain 
catalyzes the reversible acetylation of histone proteins present in nucleosomes [206]. 
Phosphorylation of CREB leads to the recruitment of the coactivators CBP/p300, 
which bind phospho-CREB through their KIX domain [200, 202]. A newer class of 
proteins referred to as TORCs, bind constitutively to the bZIP domain of CREB [207, 
208]. Both CBP and TORC2 are transcriptional coactivators that have been reported to 
modulate glucose metabolism via the CREB coactivator complex [182, 183]. Given that 
inappropriate hepatic glucose production during fasting is the most important cause of 




5.1.1 Cyclic AMP signaling in the hepatocyte 
The hepatocyte serves a critical physiological role in glucose homeostasis by 
storing or producing glucose based on the needs of the body. Binding of epinephrine, 
glucagon, and glucocorticoids to their respective G-protein coupled receptors will result 
in increased intracellular cAMP levels. In particular, following glucagon signaling, the 
cAMP signal will activate PKA, which phosphorylates the nuclear transcription factor 
CREB. The phosphorylation of CREB at S133 by PKA, leads to the recruitment of the 
nuclear coactivators CBP/p300 [209]. When CBP is phosphorylated it will not bind 
CREB. Activation of the cAMP pathway also leads to the dephosphorylation of TORC2. 
Following this event, TORC2 leaves the cytoplasm where it typically resides and enters 
the nucleus, where, like CBP, it functions as a transcriptional coactivator. As CREB, CBP 
and TORC2 (also referred to as CRTC2) assemble, glucose metabolism is modulated via 
the formation of this nuclear complex. Glucagon signaling increases hepatic glucose 
production by promoting the formation of this coactivator complex on CRE sites. 
The PPAR# coactivator 1! (PGC-1!) regulates the gluconeogenic gene program in 
the liver. Transcription of PGC1a is mediated through cAMP signaling and it contains a 
well-defined CRE site to which the coactivator complex binds through CREB [182]. 
PGC-1! is a coactivator that binds associated transcription factors such as the hepatocyte 
nuclear factor 4 and the glucocorticoid receptor to regulate transcription of genes 
involved with glucose homeostasis [210]. Glucagon activates cAMP signaling and leads 
to an increase in the transcription of PGC1a and its downstream target genes. These 




phosphoenolpyruvate carboxykinase (PEPCK, Pck1) and glucose-6-phosphatase (G6P, 
G6pc).  
5.1.2 Insulin signaling in the hepatocyte 
In the fed state, insulin is a dominant suppressor of hepatic glycogenolysis and 
gluconeogenesis. Within the hepatocyte, insulin signaling stimulates the phosphorylation 
of CBP and reduces binding to CREB, regardless of the phosphorylation state of CREB. 
As such, insulin action can cause the termination or reduction of the cAMP signal 
mediated by CREB by preventing the binding of CBP to CREB, and causing the 
dissociation of the coactivator complex. 
Previously, Wondisford and colleagues demonstrated that insulin phosphorylation 
at S436 is required for the efficient dissociation of the CREB co-activator complex and 
consequent attenuation of CREB-dependent gene transcription [182]. An in vivo mouse 
model of constitutively activated nuclear cAMP signaling was generated previously 
[211]. In this model, a germline mutation of CBP at S436 (S436A), removes a site of 
insulin-mediated phosphorylation. Without this site, CBP binds constitutively to 
phospho-CREB, and CREB-dependent gene transcription becomes resistant to the effects 
of insulin signaling. Insulin action in the hepatocyte would normally inhibit the binding 
of CBP to CREB and result in the dissociation of the coactivator complex. As a result of 
this mutation, these mice have impaired glucose tolerance due to the inappropriate 
activation of hepatic gluconeogenesis, hepatic insulin resistance, decreased insulin 
secretion from pancreatic "-cells, and increased "-cell mass [211].  
There is a conserved protein kinase C (PKC) phosphorylation site in the C/H1 




location just N-terminal to the KIX domain on CBP, and it is this residue that is 
phosphorylated. Given its close proximity to the domain thought to interact with CREB, 
and the conservation of this serine residue among different species, it seems plausible that  
 
Figure 41. CBP phosphorylation site is conserved among eukaryotic species. 
Eukaryotic species are listed on the left. The residues surrounding the phosphorylation 
site are shown in black with the conserved serine residue displayed in red [182]. 
 
phosphorylation of CBP at this residue, could serve as a means of regulating hepatic 
glucose production. Through the dissociation of the coactivator complex, hepatic 
gluconeogenesis is reduced. They have also demonstrated that phosphorylation of CBP at 
S436 by insulin-mediated signaling, via the atypical protein kinase C #/$, is essential for 
dissociation of the coactivator complex (Figure 42). 
In contrast, it has previously been suggested that the TORC (also referred to as 
CRTC) family of proteins are the predominant regulators of hepatic gluconeogenesis via 
CREB. Insulin signaling is thought to promote the phosphorylation TORC2, exclude it 
from the nucleus, and target it for proteasomal degradation (Figure 40). In this model of 
insulin regulation, S171 is phosphorylated on TORC2 leading to nuclear exclusion and 
the subsequent termination of CREB-dependent gene transcription [212]. The salt-
inducible kinase 2 (SIK2) promotes the phosphorylation of TORC2 at S171 and inhibits 
its activity on the promoters of gluconeogenic genes [212]. Additionally, insulin 
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signaling modulates the activity of TORC2 by acting through the serine/threonine kinase 
AKT, which phosphorylates SIK2 at S358. The insulin-mediated phosphorylation of 
TORC2 causes it to become sequestered in the cytoplasm where it is targeted for 
proteasomal degradation. However, in insulin-resistant states, TORC2 undergoes O-
glycosylation and is retained in the nucleus [213]. 
 
Figure 42. CBP plays central role in the regulation of hepatic glucose production. 
Glucagon signaling activates the assembly of the CREB coactivator complex. Insulin 
signaling caused the dissociation of this nuclear coactivator complex. 
Recently, CRTC2/TORC2-deficient mice were derived to assess the role of TORC2 
in hepatic glucose metabolism in vivo. After a prolonged fast, no significant difference 
was observed between the blood glucose levels of TORC2 mutants and littermate 
controls [214]. In addition, there was no difference in hepatic glucose production between 




the transcriptional response but it is most likely not a key regulator of glucose 
homeostasis.  
5.1.3 Cyclic AMP signaling in the adipocyte 
The primary function of the adipocyte is to store triglycerides that are released as 
fatty acids and glycerol during lipolysis. The storage of excess energy as triglycerides is 
central to obesity and other metabolic disorders. Diet-induced thermogenesis is activated 
by the sympathethic nervous system (SNS) to increase energy expenditure and prevent 
obesity [215, 216]. The SNS regulates energy expenditure by sensing caloric excess. It 
innervates white adipose tissue (WAT) and brown adipose tissue (BAT) but, sympathetic 
innervation is thought to be more plentiful in BAT [217]. The binding of hormones and 
catecholamines to "-adrenergic receptors ("ARs) located within the adipocyte will 
initiate a signaling cascade that stimulates lipolysis [215, 218]. "ARs coupled to G 
proteins will mediate a cAMP signaling to activate PKA. Within this signaling cascade, 
PKA has downstream effects on other proteins.  
Hormone sensitive lipase (HSL) and perilipin are both substrates of PKA, and their 
phosphorylation releases free fatty acids from triacylglycerol stored in lipid droplets 
within adipose tissue [219-222]. HSL hydrolyzes a variety of substrates including: 
triacylglycerol, diacylglycerol, and cholesterol esters. Perilipins help orchestrate the 
activity of HSL to facilitate lipolysis. They are located on the surface of the lipid droplet 
and inhibit the action of cytosolic lipases in the basal (unactivated/unphosphorylated) 
state [221]. A recent study conducted with obese women confirmed the protective effects 
of perilipin. In these women, perilipin protein content was decreased by 50% and basal 




Insulin terminates catecholamine-induced cAMP signaling through the degradative 
activity of phosphodiesterase 3, an enzyme that effectively reduces intracellular levels of 
cAMP. Hormones, cytokines, prostaglandins, nutritional inputs, gender, and physical 
activity all have an effect on lipolysis. 
Alterations in cAMP signaling have the potential to impact whole body metabolism 
and more specifically lipolysis. Given the role of cAMP-mediated signaling in lipolysis, 
it would be interesting to observe the effects of the constitutive activation of this 
signaling pathway on energy balance. It is plausible that such signaling could result in a 
disruption of whole-body metabolism, or cause an increase in energy expenditure. 
Indirect calorimetry is a method that has existed for years but is being utilized as a 
research tool more and more to assess metabolic profiles. Of late, it is being used to 
investigate thermogenesis, as well as a number of disease pathologies implicated in 
metabolic disorders. It estimates energy expenditure and substrate utilization in a non-
invasive manner through the use of gas exchange measurements. By employing indirect 
calorimetry, we can examine complex metabolic processes and correlate 
pathophysiological changes with interactions that occur on the molecular level. These 
studies will provide a better understanding of how diet-induced thermogenesis protects 
against obesity and determine how this mutation impacts metabolic rate. 
5.2 Objectives 
The overall goal of these studies was to define the structural and biophysical details 
of protein-protein interactions occurring between CREB and coactivators that result in 
the transcriptional activation of genes involved in hepatic gluconeogenesis and lipolysis. 




resulting effects on energy balance using the CBP S436A mouse as an in vivo model of 
constitutively activated nuclear cAMP signaling. Additionally, we sought to provide a 
biophysical and biochemical basis for the assembly of the cAMP coactivator complex 
through the expression and purification of recombinant protein for biophysical and 
structural studies. The methods and results of the biophysical characterization of CREB, 
CREM and CBP will follow in subsequent appendices. This overview will also serve as 
an introduction for those appendices.  
5.3 Sequence alignment of members of the basic leucine zipper family 
The amino acid sequences of three members of the bZIP superfamily that together 
form the CREB subfamily of transcription factors, were selected for multiple sequence 
alignment. Protein sequences of two isoforms of CREB (CREB1A and CREB1B), ATF-
1, and a truncated version of CREM, were aligned using Clustal Omega [162]. A figure 
containing the alignment was generated using the program ESPript [163].  
5.4 Methods for metabolic phenotyping of CBP KI mice 
5.4.1 Mouse Husbandry 
All the animal procedures were performed in accordance with protocols approved 
by the Institutional Animal Care and Use Committee of the Johns Hopkins University. 
Animals were housed in a dedicated clean barrier animal facility within the Johns 
Hopkins University School of Medicine on a 12-hour light/12-hour dark photocycle. 
Mice had ad libitum access to food and water. Their diet consisted of either normal chow 




5.4.2 Genotyping and breeding of mouse cohort 
A C57BL/6J mixed-background strain (originally obtained from Jackson 
Laboratories), bearing a heterozygous state (S436A/WT), were crossed to create both 
control and homozygous mice for this study. All mice generated for this study were from 
heterozygous pairings (S436A+/% ( S436A+/%). The generation of the CBP S436A 
mutant mouse has been described previously [211]. Tail snips of up to 5 mm were 
obtained from mice at weaning, digested overnight at 55°C in buffer containing 10 mM 
Tris-Cl pH 8.0, 100 MM NaCl, 10 mM EDTA, 0.1 mg/mL Proteinase K, and 0.5% SDS. 
Subsequently, samples were processed to isolate genomic DNA, using either 
phenol/chloroform extraction followed by 2-propanol extraction, or the Gentra Puregene 
Mouse Tail Kit (Qiagen).  
The S436A mutation was identified on genomic DNA obtained from tail snips 
using the following oligonucleotide primers: Common, 5)-GAC CTT GTT GCT TTG 
CAC TTG TTC-3); Match, 5)-CTC CCT TTG AAA AAT GCC AG-3); and Mismatch, 5)-
CTC CCT TTG AAA AAT GCC GC-3). PCR reactions proceeded for 32 cycles of 
denaturation at 95°C for 30 seconds, annealing at 61°C for 45 seconds, and extension at 
72°C for 1 minute, with a final extension at 72°C for 7 minutes. All reactions were 
performed under standard conditions using 100 ng of genomic DNA, 7.5 nmol of 
primers, buffer containing 2.5 µl of 15 nM MgCl2, and 0.5 µl of Taq polymerase per 
reaction. Reactions were run on 1% (w/v) agarose gel supplemented with ethidium 
bromide. Control mice displayed a band at the Match primer only, while CBP S436A 
mice only displayed a band at the Mismatch primer, and heterozygous mice (S436A+/%) 




5.4.3 Assessment of body composition 
The Metabolic Phenotyping Core Facility of the Johns Hopkins University School 
of Medicine performed the measurements. The EchoMRI-100 quantitative nuclear 
magnetic resonance (QNMR) system (Echo Medical Systems) was used to measure 
whole body composition parameters in CBP S436A mutant mice and age-matched 
littermate controls following consumption of normal chow or high fat diet. Direct 
measurements were taken in vivo of fat mass, lean mass, free water, and total body water. 
All measurements were performed in triplicate.  
5.4.4 Indirect Calorimetry 
Animals were separated and housed in individual cages 2 weeks prior to 
experimentation for adaptation. Only male mice were used for these studies. 
Homozygous CBP S436A mutants and control littermates were used for simultaneous 
assessments of daily changes in body weight, energy intake, and whole body metabolic 
profile in an open-flow indirect calorimeter. The Comprehensive Laboratory Animal 
Monitoring System (CLAMS, Columbus Instruments) was used to obtain these 
measurements as described below (Figure 43). Normal chow and HFD-fed mice were 
evaluated in separate studies. Mice were fed HFD for a total of 22 weeks during the 
course of these studies and metabolic assessments, with the exception of body 
composition studies, were made at the following time points following this challenge: 4 
weeks, 8 weeks, 12 weeks, and 16 weeks. 
Data were collected for 3 days to ensure that stable body weights and food intakes 
had been achieved, and to confirm acclimation to the calorimetry chambers. The data 




consumption (VO2, ml*kg%1*h%1) and carbon dioxide production (VCO2) were measured 
for each chamber every 14 min throughout the studies. Respiratory exchange ratio (RER 
= VCO2/VO2) was calculated by using CLAX Oxymax software (v. 4.02) to estimate 
relative oxidation of carbohydrate (RER = 1.0) versus lipid (RER approaching 0.7), not 
accounting for protein oxidation. Energy expenditure was calculated as EE = VO2 ( 
[3.815+ (1.232 ( RER)] [224]. Average metabolic values were calculated within subjects 
and then averaged across subjects for statistical analysis by Student's t-test, with P + 0.05, 
indicating significant group differences. Standard error was also calculated across groups. 
5.5 Results and Discussion 
CBP S436A mice were comparable in body weight to control mice at weaning and 
there was no obvious difference in length. However, on normal chow as time progressed, 
the mutants consistently weighed less than wild type littermate controls. Previously, it has 
been determined that CBP mutant mice have decreased body fat in comparison to wild 
type controls using QNMR. To probe the possible protective effects of this mutation on 
whole body metabolism, mice were challenged with high fat diet to induce metabolic 
stress. Mice were weaned onto normal chow and then switched to a high fat diet (HFD) at 
8 weeks of age to observe differences in weight gain as well as other metabolic 
parameters. 
At the start of these studies, before the introduction of HFD, control mice were 
approximately 16% heavier (29.2 ± 1.7 g) than CBP mutants (24.4 ± 1.6 g). 
Subsequently, 8 weeks after the introduction of HFD, wild type littermates on average 
gained more weight and were 20% heavier (38.8 ± 0.9 g) while homozygous mutants 




littermate controls became obese while CBP S436A mutants maintained a leaner 
phenotype (Figure 44, A). 
The differences in body weight between the homozygous mutants and littermate 
controls could be due to the accumulation of less fat mass. Not surprisingly, body 
composition analysis using quantitative NMR revealed that S436A mutants had less fat 
mass (14.1 g) relative to littermate controls (18.6 g) even after consumption of HFD for 
22 weeks (Figure 44, B). This could account for the lower total body weight observed in 
these mice. Unfortunately, we did not harvest any fat pads to further assess the 
differences in fat mass between visceral or subcutaneous fat depots. Reductions in 
adipose tissue in response to HFD can be attributed to either an increase in physical 
activity, or a decrease in food intake. There were no observable differences in physical 
activity among CBP mutants versus control mice. However, CBP mutants experienced 
lower food intake in comparison with wild type mice, and this effect was observed within 
the first four weeks on the HFD. CBP S436A mutants were largely resistant to weight 
gain or diet-induced obesity (Figure 45), in comparison to controls.  
Indirect calorimetry was performed to assess the effects of CBP S436A mutation 
on the metabolic rate. On regular chow, these analyses only revealed slight differences 
between controls and CBP mutants (data not shown). However on HFD, the differences 
between the two groups became more pronounced. To calculate RER and estimate energy 
expenditure, rates of oxygen consumption and carbon dioxide release were measured. 
Oxygen consumption is often used as a measure of basal metabolic rate. The CBP 
mutants displayed increased oxygen consumption (VO2) and carbon dioxide production 




metabolism (Figure 46). Over time, both groups shifted from the use of carbohydrates as 
a fuel source with RER near 1.0, toward a preferential utilization and oxidation of lipids 
with RER approaching 0.7 (Figure 47). Although lower average RER are expected with 
consumption of HFD, compared to littermate controls, CBP mutants had a lower RER 
after 16 weeks on HFD, especially during the dark photocycle, (0.767 ± 0.014 versus 
0.790 ± 0.015). CBP mutants experienced a greater shift toward enhanced whole-body 
oxidation of lipids, and increased energy expenditure despite hypophagia. 
Although these results are promising, these findings need to be repeated and 
confirmed with larger cohorts (N & 8) to ensure reproducibility. The preliminary results 
of this work demonstrate that increased cAMP activation does lead to disruptions in 
whole body metabolism that could possibly protect against diet-induced obesity (DIO). 
For all of the metabolic parameters evaluated (body composition, food intake, oxygen 
consumption, RER, energy expenditure), there were subtle differences between 
homozygous mutants and littermate controls at baseline that became more apparent when 
challenged with HFD. Overall, the CBP S436A mutants were hypophagic, weighed less, 
had decreased fat mass, increased oxygen consumption, enhanced metabolic rate, 
enhanced energy expenditure, and displayed a metabolic profile consistent with a shift 
towards the preferential utilization of lipids as an energy source.  
5.6 Future directions for S436A CBP mutant mouse 
It was interesting to note that the S436A homozygous mutants seemed to 
experience appetite suppression and were hypophagic throughout the duration of the 
study. More than likely, this was a contributing factor to the lean phenotype maintained 




greater postprandial response than would carbohydrates or proteins. Additionally, fasting 
levels of peptide YY (PYY) are elevated in several gastrointestinal diseases associated 
with loss of appetite [225, 226]. Following the consumption of a meal, hormones are 
released from the gastrointestinal tract, such as PYY. The anorexigenic POMC (pro-
opiomelanocortin) neurons are activated by PYY, but it also simultaneously inhibits the 
orexigenic NPY/AGRP (neuropeptide Y/agouti related peptide) neurons, and regulates 
food intake by suppressing appetite within the arcuate nucleus [227].  
The possibility remains that the CBP S436A mice have some defect in the 
hypothalamus or neural circuits that when coupled with the sustained activation of the 
cAMP pathway results in these anorexigenic effects on appetite and offers some 
protection against DIO. These mice might also secrete higher levels of PYY, and this 
could also lead to a loss of appetite and result in lower food intake. It would be 
interesting to follow up with experiments that evaluate serum levels of PYY and other gut 
hormones pre- and post-consumption of HFD to tease out what factor causes the 







Figure 43. Oxymax open-flow indirect calorimetry chambers. 
Fully automated open circuit indirect calorimeter used for metabolic studies with S436 
CBP mice. Heat is derived by assessment of the exchange of oxygen for carbon dioxide 
that occurs during the metabolic process. The relationship between the volume of gas 
consumed (oxygen) and of that produced (carbon dioxide) reveals the energy content of 
the foodstuff utilized by the subject. This ‘calorific value’ is then applied to the volume 
of gases exchanged to compute heat and calculate energy expenditure.  
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Figure 44. CBP mutants have a lean phenotype. 
Effects of HFD on weight and body composition. A) Histogram of weight gain with 
number of weeks indicating age. B) Body composition analyses after 22 weeks on HFD. 
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Figure 45. CBP mutants are resistant to diet-induced obesity.  
CBP mutants are lighter and have less fat mass than wild type controls. A) Body weight. 
B) Food intake after 4 weeks on HFD. C) Food intake after 16 weeks on HFD. 
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Figure 46. CBP mutants possess enhanced metabolism compared to controls.
Assessment of metabolic parameters following consumption of HFD over time period of 
4 weeks. A) Oxygen consumed. B) Carbon dioxide produced. C) Respiratory exchange 
ratio. D) Energy expenditure. 
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Figure 47. CBP mutants display greater energy expenditure relative to controls. 
Assessment of metabolic parameters following consumption of HFD over 16-week time 
course. A) Oxygen consumed. B) Carbon dioxide produced. C) Respiratory exchange 





6. Appendix II: Expression, Purification, and Biophysical 
Characterization of CREB and CREM 
 
6.1 Methods for expression and purification of CREB in bacterial cells  
6.1.1 Cloning and expression of CREB 
The full-length Mus musculus CREB1A gene was cloned into the TOPO vector 
(Invitrogen) following PCR amplification. These primers were used for PCR 
amplification: forward 5’-GAGAGCTCATGACCATGGAATCTGGAGCA-3’ and 
reverse 5’-GAGCGGCCGCTCATTAATCTGATTTGTGGCAGTAAAGG-3’. Plasmid 
DNA containing the cloned gene was purified and sequenced. Subsequently, both the 
insert and vectors pET-28a and pET-42a (Novagen) were digested with NotI and SacI 
(New England Biolabs). The digested ends of insert and vector were joined using T4 
liagase (New England Biolabs), and following heat inactivation for 15 minutes at 60°C, 
ligation products were transformed into DH5! cells (New England Biolabs). Several 
colonies were selected for isolation of plasmid DNA using the Fermentas Miniprep Kit 
(ThermoScientific). DNA sequencing was used to confirm the presence of the gene in the 
correct reading frame. The full-length Mus musculus CREB1A gene was also cloned into 
other vectors and used with different bacterial strains and expression systems (Table 6). 
All methods for cloning CREB in bacterial cells were similar to those listed in this 
section with the exception of the use of different restriction enzymes and antibiotics 




Plasmid DNA of CREB was used to transform E. coli BL21 (DE3) cells 
(Novagen). Cells were grown overnight at 37°C in LB medium supplemented with 100 
µg/mL kanamycin and used to inoculate cultures the following morning. Eight liters of 
bacterial cells were grown at 37°C in LB medium supplemented with 50 µg/mL 
kanamycin to 0.8 at A600. Protein expression was induced with the addition of 0.4 mM 
IPTG and growth was continued at 18°C overnight. Cells were harvested by 
centrifugation and washed with 50 mM sodium phosphate pH 8.0, 300 mM NaCl, 10 mM 
imidazole, and 10 mM "-mercaptoethanol. Following this wash step, cells were 
subsequently pelleted and stored at %80°C. 
6.1.2 Protein purification of CREB 
Cell pellets were resuspended in buffer A (50 mM sodium phosphate pH 8.0, 300 
mM NaCl, 10 mM imidazole, and 10 mM "-mercaptoethanol,) and lysed by 
microfluidization. The lysate was fractionated into the soluble cytoplasmic fraction by 
centrifugation at 12,000 rpm at 4°C for 30 minutes. The soluble cytoplasmic fraction was 
then filtered using 0.2 µm filter. Supernatant containing CREB protein was loaded onto a 
HisTrap HP 5 mL column (GE Healthcare) pre-equilibrated with buffer A. CREB was 
eluted using an imidazole gradient with 0-100% elution buffer B (50 mM sodium 
phosphate pH 8.0, 300 mM NaCl, 250 mM imidazole, 10 mM "-mercaptoethanol). All 
fractions were collected and subjected to SDS-PAGE analysis (Figure 48). Fractions were 
pooled for dialysis against 1 L of dialysis buffer (20 mM Tris pH 8.5, 50 mM NaCl, and 
10 mM "-mercaptoethanol). Dialysis buffer was filtered and used as binding and 
equilibration buffer for anion exchange chromatography. If any protein remained 




Unbound protein was removed with 5 column volumes of binding buffer and target 
protein eluted with a gradient up to 100% of buffer containing 20 mM Tris pH 8.5, 1 M 
NaCl, and 10 mM "-mercaptoethanol over 20 column volumes (Figure 49). Fractions 
containing protein were pooled and concentration was attempted.  
6.2 Methods for cloning, expression, and purification of CREB in insect cells 
6.2.1 Production of bacmid DNA and transformation into DH10Bac cells 
Full-length CREB was codon optimized for expression in insect cells (Figure 50), 
and cloned into the pFastBacHTC vector using SalI and HindIII as restriction sites by 
GeneScript. Stocks of pFastBacHTC-CREB were prepared using sterile ddH2O. 
DH10Bac competent cells were thawed on ice before incubation with plasmid DNA. 
DNA at a concentration of 1 ng/µL was added to 100 µL of cells. Incubation proceeded 
for 30 minutes on ice, followed by heat shock at 42°C for 45 seconds, and cells were then 
transferred to ice for 5 minutes. S.O.C. medium (Invitrogen) was added (900 µL) to bring 
final volume to 1 mL, and cells were grown at 37°C with agitation at 220 rpm for 60 
minutes. LB agar plates containing 7 µg/mL gentamycin, 50 µg/mL kanamycin, 10 
µg/mL tetracycline, 100 µg/mL 5-bromo-4-chloro-3-indolyl-"-D-galactopyranoside (X-
gal), and 40 µg/mL IPTG were plated with either 100 µL of cells or 10 µL of cells mixed 
with 90 µL of S.O.C. media. Plates were incubated at 37°C for 48 hours and monitored 
for the appearance of blue or white colony growth. White colonies were selected and re-
streaked onto fresh agar plates for 48 hours to ensure the colonies contained true 




6.2.2 Colony PCR 
PCR reactions were prepared in thin-walled PCR tubes (Sigma) with all of the 
necessary components (Table 5). M13 forward 5’-GTTTTCCCAGTCACGAC-3’ and 
reverse 5’-CAGGAAACAGCTATGAC-3’primers were used. A 20 µL tip was used to 
scrape cells from agar plates and this tip was incubated for 5 minutes in PCR tube with 
the other reaction components before pipetting to evenly distribute cell into the solution. 
The reaction proceeded with an initial denaturation step at 93°C for 3 minutes to lyse 
cells, followed by thirty cycles of denaturation at 94°C for 30 seconds, annealing at 55°C 
for 30 seconds, extension at 72°C for 3 minutes and 30 seconds (60 seconds per kb length 
of PCR product), and final extension step at 72°C for 5 minutes. A 0.7% agarose gel 
(w/v) was used to visualize PCR products and confirm presence of band at expected 
lengths.  
Table 5. Reaction conditions for colony PCR. 
Reaction Component Amount Used Supplier 
ddH20 41.4 µL  
10X Reaction Buffer 5.0 µL Invitrogen 
10 mM dNTP Mix 1.0 µL New England Biolabs 
50 mM MgCl2 1.5 µL New England Biolabs 
40 µM Forward Primer 0.3 µL Integrated DNA Tech. 
40 µM Reverse Primer 0.3 µL Integrated DNA Tech. 
Platinum Taq (5U/µL) 0.5 µL Invitrogen 
 
6.2.3 Isolation of Bacmid DNA 
Cultures of DH10Bac cells (10 mL) were prepared with LB media supplemented 




for each bacmid and grown overnight at 37°C for 16 hours at 220 rpm. Cells were 
harvested using centrifugation at 3500 ( g for 10 minutes. Qiagen miniprep kit was used 
to isolate bacmid DNA. Buffer P1 (250 µL) was used to resuspend the cells and 
transferred to microcentrifuge tube. Buffer P2 (250 µL) was added to lyse cells and 
inverted gently 6 times to ensure homogeneity. The suspension was incubated at RT for 5 
minutes before 350 µL of buffer N3 was added and inverted gently 6 times to precipate 
DNA. Cellular debris was pelleted at 12,000 ( g on a microcentrifuge. Pre-chilled 
isopropanol (700 µL) was added to clean microcentrifuge tubes before the addition of 750 
µL supernatant. Tubes were inverted 6 times before incubating on ice for 10 minutes, 
followed by a centrifugation at 12,000 ( g for 15 minutes to pellet DNA. The supernatant 
was removed by gently pipetting so as not to disturb pellet. Pre-chilled 70% ethanol (500 
µL) was added to wash the pellet by inverting tube 6 times. Tubes were centrifuged at 
12,000 ( g for 5 minutes and this wash step, followed by centrifugation, was repeated 
once before drying DNA pellets in sterile tissue culture hood for approximately 30 
minutes. DNA was dissolved in 40 µL of TE buffer and concentrations were determined 
using the Nanodrop. Bacmid DNA was stored at 4°C for no longer than two weeks. 
6.2.4 Baculovirus production 
Sf9 cells were seeded onto 6-well plates at a density of 1 ( 106 cells in a total 
volume of 2 mL and grown at 27°C overnight. The following day plates were typically 
70-80% confluent. For each transfection, liposome-DNA complexes were prepared: 6 µL 
of Cellfectin I (Invitrogen) was added to 100 µL of Grace’s insect cell media 
(Invitrogen), and 3 µL of of bacmid DNA were added to 100 µL of Grace’s insect cell 




and incubated for 30 to 45 minutes before the addition of 800 µL of Grace’s insect cell 
media. Grace’s insect cell media was added to each well to wash the cells and media was 
removed from each well by aspiration. Liposome-DNA complexes (1 mL) were added to 
the cells and allowed to incubate for 5 hours at 27°C. Media was removed by aspiration 
and 2 mL complete media was added, Sf900IIISFM media (Invitrogen) supplemented 
with antibiotics and returned to 27°C. After 72 hours, media containing P1 virus was 
transferred to a microcentrifuge tube. Cells were pelleted for 5 minutes at 500 ( g and 2% 
FBS was added to the supernatant containing P1 virus and stored at 4°C. To amplify P1 
virus for P2 virus production, cells were seeded to 11 ( 106 in a volume of 10 mL in a 
T75 flask. Cells were incubated overnight at 27°C and typically reached 70-80% 
confluency the following day. P1 viral stock (400 µL) was added to infect for 
approximately 65 hours. Media was removed and cells pelleted at 500 ( g for 10 minutes. 
FBS was added to 2% to the supernatant containing P2 viral stock and stored at 4°C. P3 
viral stock was propagated as outlined with the only exception being that P2 viral stock 
was used to generate P3 and only 250 µL were used to initiate infection. P3 viral stocks 
were used for protein expression. 
6.2.5 Maintenance of insect cells 
All cell maintenance was performed using aseptic technique under a sterile tissue 
culture hood. Cell density was determined using a hemacytometer. Sf9 insect cells were 
thawed from liquid nitrogen stocks and used to initiate new maintenance cultures. A 1.5 
mL cryovial (Nalgene) containing cells at a density of 10 ( 106 cells/mL was placed in a 
15 mL conical tube and cells were pelleted for 5 minutes at 500 ( g. The vial was 




resuspended with 1 mL of Sf900IIISFM media and transferred to a 25 mL spinner flask. 
An additional 1 mL of media was added to resuspend any remaining cells and the total 
volume in flask was brought to 15 mL with additional media. The spinner flask was 
placed on a cell stirrer at a stirring rate of 85 rpm. Once cells reached a density greater 
than 2 ( 106 cells/mL, additional media was added and growth continued until cells 
reached a density of approximately 3.5 ( 106 cells/mL and then transferred to 125 mL 
spinner flask and culture passaged to a density of approximately 1 ( 106 cells/mL. 
Subsequently, insect cells were transferred into larger spinner flasks once they reached a 
certain density. Typically cells were transferred into 125 mL spinner flask, followed by 
transfer to 500 mL spinner flask and then moved to a 1 L or 3 L spinner flask. Aeration 
was only used with 1 L or 3 L spinner flasks. As such, cells were generally passaged at 
least three to four times before protein expression was performed. Cells were discarded 
after reaching a passage number of 30. Following use, spinner flasks were treated with a 
10% solution of bleach and washed thoroughly before sterilization. Flasks were 
autoclaved for a minimum of two dry cycles of 50 minutes of sterilization, followed by 
15 minutes of drying time. Caps were loosened for autoclaving but tightened before 
removing flask from autoclave and stored until use. 
6.2.6 CREB expression in insect cells 
For protein expression, 2.5 L of Sf9 cells were grown to a density of 3.5 ( 106 
cells/mL in a 3 L spinner flask. Before protein expression was initiated, 30-40 mL of 
cells were removed from the flask to continue a maintenance culture. P3 viral stock in the 
amount of 50 mL was used for protein expression, and 40 µL of a 10 mM stock of PKA 




was monitored but typically remained constant after viral infection. Cells were harvested 
62 to 67 hours post-infection by centrifugation for 15 minutes at 500 ( g. Insect cell 
pellets were stored at %80°C until use. 
6.2.7 Protein purification of CREB 
Insect cell pellets were thawed in a beaker containing room temperature water and 
resuspended in buffer containing 50 mM sodium phosphate pH 8.0, 300 mM NaCl, 10 
mM imidazole, 0.1% Triton X-100, 10 mM "-mercaptoethanol, with one dissolved 
Complete EDTA-free protease inhibitor tablet (Roche). Sonication was used to lyse cells 
at a 25% duty cycle for 1min with three second pulses and a one second pause in between 
pulses. Cellular debris was pelleted by centrifugation at 18,000 rpm at 4°C for 30 minutes 
using a Sorvall SS-34 rotor. The soluble cytoplasmic fraction was filtered with 0.2 µm 
SFCA-PF syringe filters (Corning) followed by another filtering step using 0.2 µm 
Stericup filters (Millipore). CREB protein lysate was incubated with 1 mL of a 50/50 
slurry of Ni-NTA agarose beads (Qiagen) for 2 hours at 4°C with agitation. Beads were 
pelleted at low speed using centrifugation and washed with binding buffer (50 mM 
sodium phosphate pH 8.0, 300 mM NaCl, 10 mM imidazole, and 10 mM "-
mercaptoethanol), for three 5 mL washes. Protein was eluted stepwise with 1 mL of 
buffer containing 50 mM sodium phosphate pH 8.0, 300 mM NaCl, and 10 mM "-
mercaptoethanol with varying concentrations of imidazole (50 mM, 100 mM, 150 mM, 
or 250 mM) for a total of 12 washes. Fractions were analyzed by SDS-PAGE (Figure 51, 
B) and pooled for dialysis against 1 L of dialysis buffer (20 mM Tris pH 8.0, 50 mM 
NaCl, and 10 mM "-mercaptoethanol). Dialysis buffer was filtered and used as binding 




pre-equilibrated Mono Q 5/50 column (GE Healthcare). Unbound protein was removed 
with 5 column volumes of binding buffer and target protein eluted with a gradient up to 
100% of buffer containing 20 mM Tris pH 8.0, 1 M NaCl, and 10 mM "-mercaptoethanol 
over 20 column volumes (Figure 51, A and C). Fractions containing protein were pooled 
and dialyzed sequentially into 20 mM Tris pH 8.0, 100 mM NaCl, and 10 mM "-
mercaptoethanol and concentrated to approximately 10 mg/mL for storage at %80°C.  
6.2.8 Screening of crystallization conditions  
CREB protein was screened for crystallization at a concentration of approximately 
10 mg/mL. Recombinant protein was expressed in the soluble cell lysate from insect 
cells. Hanging drops consisting of 300 nL of protein were mixed with 300 nL of reservoir 
solution using the Mosquito (TTP Labtech). The total reservoir volume was 100 µL. 
CREB protein and CRE DNA were mixed in an equimolar ratio (Figure 52) for the 
screen with Natrix Screen HT (Hampton Research). However, only CREB protein was 
used for the screens with MPD, PEGRx 1 and 2. Trays were incubated at 20 °C. 
 
Table 6. Expression systems utilized for production of CREB protein. 
Construct Expression System Problem 
pET-42a-CREB T7 Co-purified with tag 
pET-28a-CREB T7 Precipitates easily 
pET-28a-CREB RosettaGami/T7 Low expression 
pFastBacHTC-CREB Bac-to-Bac Low expression 





6.3 Results and Discussion 
Several full-length CREB constructs were used for protein expression in bacterial 
cells and insect cells. Many attempts were made to increase the expression of protein in 
different host systems. To ensure that certain post-translational modifications were made, 
we switched to a eukaryotic expression system. In particular the plasmid, pFastBacHTC-
CREB was codon-optimized to increase expression in insect cells. Additionally the PKA 
inhibitor H-89 was also used in the hopes of increasing insect cell expression [228]. 
Although protein was present in the soluble fraction, most constructs were not well-
behaved.  
Overall, protein was hard to obtain in appreciable amounts for crystallization 
screens and would often precipitate at different purification steps, or while concentrating 
protein. X-ray quality crystals were not obtained. Several crystallization attempts were 
made with CREB but only one screen yielded crystals; however, these crystals were not 
large enough for x-ray diffraction. Additionally we used the XtalPred web server to 
predict the crystallizability of CREB [229]. A prediction is made based on a comparison 
of different protein features with those present in a target database [230]. CREB contains 
a long disordered region as well as other features that make crystallization difficult. It 
belongs to the class with the highest degree of difficulty and the results are summarized 









Figure 48. Ni2+-affinity chromatography of CREB.
(A) Chromatogram of first step of purification. Blue line denotes absorbance at 280 nm in 
milliabsorbance units and green line represents gradient of buffer used for elution. Pink 
line denotes sample injection. (B) SDS-PAGE gel of purification stained with Coomassie
blue stain. M refers to molecular weight ladder in kilodaltons and L to sample loaded 
onto column. Fractions corresponding to peak are shown. 
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Figure 49. Anion exchange chromatography of CREB. 
(A) Chromatogram of second step of purification. Blue line denotes absorbance at 280 
nm and green line represents gradient of buffer used for elution with concentration listed 
on right axis. Pink line denotes sample injection. (B) SDS-PAGE gel of purification 
stained with Coomassie blue stain. M refers to molecular weight ladder, D fractions after 
dialysis, and L to sample loaded. Fractions corresponding to peak are shown. 
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Figure 50. Codon optimization of CREB for insect cell expression. 
Adjustment of codon usage bias and GC (guanine and cytosine) content. The original 
values are displayed in blue while values following optimization are displayed in green.
(A) Distribution of codon usage frequency along length of gene. A CAI of 1.0 is 
considered perfect and value > 0.9 is regarded as very good n terms of gene expression 
level. (B) The percentage of distribution of codons in computed codon quality groups. 
The value of 100 is set for the codon with highest usage frequency for a given amino acid 
in desired organism (insect). (C) The ideal percentage range of GC content is between 
30-70%. Peaks of GC content in a 60 base pair window were removed. 
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Figure 51. Purification of CREB expressed in insect cells. 
(A) Chromatogram of 2ND step of purification with anion exchange chromatography. 
Blue line denotes absorbance at 280 nm and green line represents gradient of elution 
buffer. Pink line denotes sample injection. (B) SDS-PAGE gel of Ni2+-affinity 
chromatography purification. M refers to molecular weight ladder, L to sample loaded, W 
to wash steps, E to elution steps. (C) SDS-PAGE gel of anion exchange. D refers to 
pooled samples after dialysis and fractions corresponding to peaks are shown. 
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Figure 52. Crystals of CREB in complex with CRE. 
CREB protein and CRE (DNA duplex) were mixed in an equimolar ratio and crystals 




Figure 53. Crystallization probability analysis of CREB. 
(A) Histograms representing comparison of target features with distribution probabilities 
obtained for: length, isoelectric point, gravity index, length of disordered regions, 
instability, percentage of coil structures, and number of coiled coils displayed for CREB. 
(B) Crystallization class with total length, gravity index, instability index, and longest 




6.4 Sequence alignment of CREB and CREM 
The amino acid sequences of CREB and CREM were selected for sequence 
alignment. Protein sequences of full-length CREB1A and CREB1B, and a truncated 
version of CREM were aligned using Clustal Omega [162]. The figure containing the 
alignment was generated using the program ESPript [163].  
6.5 Methods for expression, purification, and biophysical characterization of CREM 
6.5.1 Expression and purification of CREM 
A clone containing a truncated form of the Homo sapiens CREM gene (amino acid 
residues 21-292) was obtained from the DNASU plasmid repository. Plasmid DNA of 
CREM was used to transform E. coli BL21 (DE3) cells (Novagen). Cells were grown 
overnight at 37°C in LB medium supplemented with 100 µg/mL ampicillin and used to 
inoculate 6 liters of Autoinduction Media containing the following: 1% tryptone, 0.5% 
yeast extract, 25 mM Na2HPO4, 25 mM KH2PO4, 50 mM NH4Cl, 5 mM Na2SO4, 2 mM 
MgSO4, 54 mM glycerol, 2.8 mM glucose, and 5.6 mM !-lactose. Cells were grown at 
18°C, protein expression was auto-induced, and growth continued overnight. Cells were 
harvested by centrifugation and washed with 50 mM sodium phosphate pH 8.0, 300 mM 
NaCl, 10 mM imidazole, 0.1% Triton X-100, and 10 mM "-mercaptoethanol. Following 
this wash step, cells were subsequently pelleted and stored at %80°C. 
After thawing, cells were resuspended in lysis buffer: 50 mM sodium phosphate pH 
8.0, 300 mM NaCl, 10 mM imidazole, 0.1% Triton X-100, and 10 mM "-
mercaptoethanol, with one dissolved Complete EDTA-free protease inhibitor tablet 




centrifugation on a Sorvall GSA rotor for 30 minutes at 12,000 rpm. The lysate was 
filtered through a 0.2 µm filter and loaded onto a HisTrap HP 5 mL column (GE 
Healthcare) pre-equilibrated with buffer containing 50 mM sodium phosphate pH 8.0, 
300 mM NaCl, 10 mM imidazole, and 10 mM "-mercaptoethanol. Unbound proteins 
were washed for 5 column volumes with this buffer. Target protein was eluted using a 
segmented imidazole gradient with 12–100% elution buffer containing 50 mM sodium 
phosphate pH 8.0, 300 mM NaCl, 250 mM imidazole, and 10 mM "-mercaptoethanol. 
First step to 12% over 20 column volumes, followed by holding step that continued at 
12% for 10 column volumes, with subsequent gradient to 35% over 20 column volumes, 
and to 100% over 10 column volumes in final step (Figure 55, A). SDS-PAGE analysis 
was used to analyze fractions that contained protein (Figure 55, B). Fractions containing 
protein were pooled and dialyzed using 10 kD MWCO membrane (Pierce Snakeskin) 
against an excess of buffer containing 20 mM Tris-Cl pH 8.0, 300 mM NaCl, and 5 mM 
"-mercaptoethanol. Tobacco Etch Virus (TEV) protease was added at 4°C with agitation 
overnight. The following morning, protein was loaded onto HisTrap HP 5 mL column 
(GE Healthcare) pre-equilibrated with filtered dialysis buffer supplemented with 10 mM 
imidazole, to separate protein from tag. Elution buffer containing 20 mM Tris-Cl pH 8.0, 
300 mM NaCl, 250 mM imidazole, and 5 mM "-mercaptoethanol used to elute uncleaved 
protein and bound tag from column. Unbound flow-through fractions containing tag-free 
protein were pooled and analyzed using SDS-PAGE analysis (Figure 56).  
Fractions containing target protein were dialyzed twice against 2L of binding buffer 
(20 mM Tris-Cl pH 8.8, 50 mM NaCl, and 5 mM "-mercaptoethanol) for a total of 5 




equilibration and binding buffer for the next step of purification. The protein was further 
purified using anion exchange chromatography over a Source Q column (GE Healthcare). 
The column was pre-equilibrated with buffer A (20 mM Tris-Cl pH 8.8, 50 mM NaCl, 
and 5 mM "-mercaptoethanol) before applying protein sample over the column. Unbound 
proteins were washed with 4 column volumes of buffer A with target protein eluted with 
a gradient to 100% of buffer B (20 mM Tris-Cl pH 8.8, 1 M NaCl, and 5 mM "-
mercaptoethanol) over 20 column volumes (Figure 57). Fractions of protein containing & 
95% purity were collected and dialyzed against an excess of buffer containing 20 mM 
Tris-Cl pH 8.0, 300 mM NaCl, and 5 mM "-mercaptoethanol. Protein was concentrated 
to 1.5 mL and subjected to gel filtration chromatography using a Superose 12 10/300 GL 
column (GE Healthcare). Isocratic elution of protein was obtained with buffer containing 
20 mM Tris-Cl pH 8.0, 150 mM NaCl, and 10 mM "-mercaptoethanol, and protein was 
eluted in one column volume (Figure 58). Fractions of protein corresponding to the peak 
were concentrated to 10-15 mg/mL, and stored at %80°C. 
6.5.2 Expression and purification of TEV protease 
A plasmid containing TEV protease was re-streaked onto an LB agar plate from a 
glycerol stock. A single colony was selected from plate and used to grow an overnight 
culture in Terrific Broth supplemented with 100 µg/mL ampicillin at 37°C. The overnight 
culture was used to inoculate 4 L of Terrific Broth and grown at 37°C until 1.0 at A600. 
Protein expression was induced with the addition of 1 mM IPTG and growth was 
continued at 17°C overnight. Cells were harvested by centrifugation and washed with 50 




mM "-mercaptoethanol. Following this wash step, cells were subsequently pelleted and 
stored at %80°C. 
Bacterial cell pellets were thawed and resuspended in buffer containing 50 mM 
sodium phosphate pH 7.5, 400 mM NaCl, 10 mM imidazole, 10% glycerol, and 5 mM "-
mercaptoethanol, and lysed by microfluidization. The lysate was fractionated into the 
soluble cytoplasmic fraction by centrifugation at 12,000 rpm at 4°C for 30 minutes. The 
soluble cytoplasmic fraction was then filtered using 0.2 µm filter. Supernatant containing 
Protein was loaded onto a HisTrap HP 5 mL column (GE Healthcare) pre-equilibrated 
with the same buffer listed above. TEV was eluted using an imidazole gradient with 0-
100% elution buffer with 50 mM sodium phosphate pH 8.0, 400 mM NaCl, 250 mM 
imidazole, 10% glycerol and 5 mM "-mercaptoethanol. All fractions were collected and 
subjected to SDS-PAGE analysis (Figure 59). Fractions containing target protein were 
pooled and dialyzed against 2 L of 50 mM Tris-Cl pH 7.5, 50 mM NaCl, 10% glycerol, 
and 5 mM "-mercaptoethanol for one hour at 4°C. Dialysis continued for an additional 3 
hours with fresh buffer and sample was placed at 4°C overnight.  
Dialyzed sample was centrifuged at 10,000 rpm for 20 minutes using a Sorvall 
GSA rotor and the supernatant filtered with a 0.2 µm filter. The protein was further 
purified using cation exchange chromatography over a Source S column (GE Healthcare) 
pre-equilibrated with buffer A (50 mM Tris-Cl pH 7.5, 50 mM NaCl, 10% glycerol, and 
5 mM "-mercaptoethanol), before applying protein sample over the column. Target 
protein was eluted with a gradient to 100% of buffer B (50 mM Tris-Cl pH 7.5, 1 M 
NaCl, 10% glycerol, and 5 mM "-mercaptoethanol) over 20 column volumes (Figure 60). 




determined. TEV was diluted to 1mg/mL with storage buffer containing 50 mM Tris-Cl 
pH 7.4, 200 mM NaCl, 40% glycerol, and 5 mM "-mercaptoethanol, and stored in 1.2 
mL aliquots at %80°C. 
6.5.3 Screening of crystallization conditions 
Recombinant protein was expressed in the soluble cell lysate from bacterial cells. 
CREM was screened for crystallization at concentrations between 10-15 mg/mL. 
Hanging drops consisting of 300 nL of protein were mixed with 300 nL of reservoir 
solution using the Mosquito (TTP Labtech). The total reservoir volume was 100 µL. The 
following screens were used: Natrix Screen HT (Hampton Research), MPD (Qiagen), 
Crystal Screen I and II, Salt Rx HT, and PEGRx HT (Hampton Research). CREM protein 
and CRE DNA were mixed in an equimolar ratio for the screens with Natrix HT, MPD, 
and Crystal Screen I and II, but only CREM protein was used for the screens with Salt Rx 
HT, PEGRx HT. Trays were incubated at 20 °C. 
6.5.4 Overview and methods used for small angle X-ray scattering 
Small-angle X-ray scattering (SAXS) is a biophysical technique that can provide 
information about the size and shape of macromolecules in solution [231-233]. A pure 
protein sample that is homogenous in solution is exposed to a collimated beam of X-rays, 
and the scattering intensity is recorded as a function of the scattering angle. In contrast to 
X-ray crystallography, no crystals are needed for data collection and the solution profiles 
are continuous and radially symmetric. One disadvantage of this method relative to X-ray 
crystallography is that it does not provide information about atomic coordinates. In order 




from SAXS is spatially averaged and is of low resolution [232, 234, 235]. Modeling 
programs are used to calculate the molecular envelope of the macromolecule ab initio. 
Prior to SAXS, protein samples should be subjected to gel filtration to ensure that 
the sample is monodispersed and of high purity (& 95%) [236]. Purity should be 
confirmed by SDS-PAGE analysis. It is also imperative that matched solvent blanks are 
used for scattering data analysis. Macromolecules in solution as well as buffer molecules 
will give rise to elastic X-ray scattering when bombarded. Scattering data should be 
obtained for both buffered protein samples as well as matched solvent in the absence of 
protein. Solvent subtraction is performed to remove scattering data generated solely from 
the solvent and obtain scattering from the macromolecule. A scattering profile is 
generated for the macromolecule or complex and this profile is subsequently converted 
into a one dimensional scattering curve I(q). The resulting scattering curve is best 
described as a spherically averaged molecular envelope. The pair distribution function 
P(r) can be calculated by indirect Fourier transform of I(q), and describes the distance 
between electron pairs within the macromolecule [237]. It is a space representation of the 
scattering data. A P(r) plot utilizing the Guinier approximation can be used to calculate 
the radius of gyration (RG) and the maximum particle dimension (Dmax) of the protein 
[232, 237]. The RG refers to the distance of an object’s parts from its center of gravity or 
from an axis.  
Wide-angle X-ray scattering (WAXS) and SAXS data were collected at the 
National Synchrotron Light Source Beamline X9 of the BNL. Protein samples were 
aliquoted into PCR tubes and centrifuged at 12,000 ( g on a microcentrifuge and an 




were used. Replicates for each sample were averaged and buffer scattering profiles were 
used to extract buffer from the data. The ATSAS software suite was used for data 
analysis. The program PRIMUS was used to process data and establish parameters and 
cut-off points for data analysis [238]. The program GNOM was used to analyze the P(r) 
pair distributions as a function of Dmax [237]. The output from GNOM was used in the ab 
initio modeling program DAMMIF to generate a molecular envelope through multiple 
iterations [239]. In the initial model, dummy beads act as placeholders for solvent or 
particles. DAMMIF assumes the protein is spherical with a radius equal to Dmax and the 
interior is filled with dummy beads. Restrictions are imposed in the solution space to 
ensure particle beads are connected and tightly packed. The model is optimized through 
simulated annealing and the process repeated until the scattering data of the modeled 
shape fits the experimental data. For each sample, DAMMIF generated 10 models and 
the program DAMAVER was used to align and average the models, to converge on the 
most likely conformation based on the data [240]. 
6.6 Results and Discussion 
Little is known about CREM at the atomic level, and we had hoped it would be 
amenable to biophysical characterization. Crystallization attempts were made with 
CREM but all attempts were unsuccessful. Additionally, given its high sequence 
similarity to CREB (Figure 54), we hoped to assess the protein-protein interactions 
between CREM and CBP and apply this information to better our understanding of 
binding interactions between members of the bZIP family of transcription factors and 




determined the P(r) function derived from the SAXS profile (Figure 61, B). We generated 
ab initio models of CRE (Figure 62) and CREM in complex with CRE (Figure 63).  
 
Figure 54. CREB and CREM are similar. 
CREB and CREM function as activators or repressors of transcription. They bind CRE 
sites located within gene promoters with high. Conserved residues are displayed in blue 
and open circles denote deleted portions of the CREM construct used in our studies. 




                                                                            creb1a 
1       10        20        30        40        50        60        70      
creb1a                     EN       Q    T          A         VQ   G         Q   P A  V  Q A LAQV AA  TSSA VT     AAQ SMTMESGADNQQSGDAAVTE QQMT QA P I SMP H PT L LPN QTVQVHGVI
creb1b                     EN       Q    T          A         VQ   G         Q   P A  V  Q A LAQV AA  TSSA VT     AAQ SMTMESGADNQQSGDAAVTE QQMT QA P I SMP H PT L LPN QTVQVHGVI
cremasu                     EN       Q    T          A         VQ   G         Q   P S  L  T E VESQ SI  SLTE SA     NSI A................... .... YF S M HDG T SK H TQT .........
                                                                            creb1a 
  80                      90       100       110       120       130        
creb1a   Q                         IAE   S ES   V DS KRREILSRRPSYRKILN LSSD PGVP IEVI IST   S  Q   T                       A    R  SPQVQTVQ.............. ED VDS Q D
creb1b   Q                         IAE   S ES   V DS KRREILSRRPSYRKILN LSSD PGVP IEVI IST   S  Q   T                       A    R  SPQVQTVQSSCKDLKRLFSGTQ ED VDS Q D
cremasu   Q                         IAE   S ES   V DS KRREILSRRPSYRKILN LSSD PGVP IELA VAA   T  A   I                       V    K  ...................... DE GG. H E
                                                                            creb1a 
140       150       160       170       180       190       200       210    
creb1a EE SEEE   P I T  VPT IYQTS GQYIAI QGG IQ  N G DGVQGLQ LTMTN  A  PG TI QY AQ   K    S  A T T        S      T   A  LA  T       T     A    T  L    TT A V P N A TQ .
creb1b EE SEEE   P I T  VPT IYQTS GQYIAI QGG IQ  N G DGVQGLQ LTMTN  A  PG TI QY AQ   K    S  A T T        S      T   A  LA  T       T     A    T  L    TT A V P N A TQ .
cremasu EE SEEE   P I T  VPT IYQTS GQYIAI QGG IQ  N G DGVQGLQ LTMTN  A  PG TI QY AQ   R    T  S A A        T      A   T  IS  S       A     S    A  V    SG P M S P G PP A
                                                                            creb1a 
     220       230       240       250          260       270       280     
creb1a  DG QQ  VP  QVVVQAA GD  TYQIR APT     GVVMA SP     P Q AEEA RKRE RLMKNREAA ET      N       S          STI      S  L T     A    V         R . IL S VQ T AP ...A P
creb1b  DG QQ  VP  QVVVQAA GD  TYQIR APT     GVVMA SP     P Q AEEA RKRE RLMKNREAA ET      N       S          STI      S  L T     A    V         R . IL S VQ T AP ...A P
cremasu  DG QQ  VP  QVVVQAA GD  TYQIR APT     GVVMA SP     P Q AEEA RKRE RLMKNREAA EA      S       T          AAL      A  S Q     T    L         K T FF G MP . PQ GSLH L
                                     TT                                     creb1a 
  290       300       310       320                                         
creb1a CRR KKE                                                                        K   YVKCLENRVAVLENQNKTLIEELKALKDLYCHKSD
creb1b CRR KKE                                                                        K   YVKCLENRVAVLENQNKTLIEELKALKDLYCHKSD





Figure 55. Ni2+-affinity chromatography of CREM.
(A) Chromatogram of CREM purification. Blue line denotes absorbance at 280 nm in 
milliabsorbance units and green line represents concentration gradient of buffer used for 
elution. Pink line denotes sample injection. (B) SDS-PAGE gel of purification stained 
with Coomassie blue stain. M refers to molecular weight ladder, P to pellet, L to sample 
loaded, FT to unbound protein. Fractions corresponding to peak are shown. 
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Figure 56. Ni2+-affinity chromatography of CREM after TEV cleavage. 
(A) Chromatogram of CREM purification. Blue line denotes absorbance at 280 nm and 
green line denotes concentration gradient used for elution. Pink line denotes sample 
injection. (B) SDS-PAGE gel of purification stained with Coomassie blue stain. M refers 
to molecular weight ladder in kilodaltons, C to sample before TEV protease cleavage, L 
to sample loaded, FT to unbound/tag-free protein. Peak fractions are displayed. 
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Figure 57. Anion exchange chromatography of CREM. 
(A) Chromatogram of purification. Blue line denotes absorbance at 280 nm in 
milliabsorbance units and green line represents gradient of buffer used for elution with 
concentration listed on right axis. Pink line denotes sample injection. (B) SDS-PAGE gel 
of purification stained with Coomassie blue stain. MWT refers to molecular weight 
ladder in kilodaltons and L to sample loaded onto column. Fractions corresponding to 
peak are shown. 
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Figure 58. Gel filtration chromatography of CREM. 
(A) Chromatogram of purification. Blue line denotes absorbance at 280 nm in 
milliabsorbance units. Pink line denotes sample injection. (B) SDS-PAGE gel of 
purification stained with Coomassie blue stain. M refers to molecular weight ladder in 
kilodaltons and fractions corresponding to peak are shown. 
128
 
Figure 59. Ni2+-affinity chromatography of TEV protease. 
(A) Chromatogram displaying 1ST step of purification. Green line represents gradient of 
elution buffer and blue line denotes absorbance at 280 nm. Pink line denotes sample 
injection. (B) SDS-PAGE gel of purification stained with Coomassie blue stain. M refers 
to molecular weight ladder in kilodaltons, L to sample loaded, and FT to unbound 
protein. Fractions corresponding to peak are shown. 
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Figure 60. Cation exchange chromatography of TEV protease. 
(A) Chromatogram of purification. The blue line denotes absorbance at 280 nm and green 
line represents gradient of buffer used for elution with concentration listed on right axis. 
Pink line denotes sample injection. (B) SDS-PAGE gel of purification stained with 
Coomassie blue stain. M refers to molecular weight ladder in kilodaltons and L to sample 
loaded onto column. Fractions corresponding to peak are shown. 
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Figure 61. Scattering data and function derived from SAXS profile. 
(A) Scattering intensities for CRE shown in red and CREM in complex with CRE are 
shown in green. (B) P(r) function derived from SAXS profile of CRE shown in red and 
for CREM in complex with CRE shown in green. 
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Figure 62. SAXS ab initio modeling results for CRE. 
The ab initio modeling results for CRE are shown in pink and purple. The averaged ab 
initio envelope generated from the modeling results is shown in blue. 
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Figure 63. SAXS ab initio model of CREM and CRE. 
The ab initio modeling results for CREM plus CRE are shown in gray, purple, pink and 
green. The averaged ab initio envelope generated from the modeling results for CREM in 




7. Appendix III: Expression, Purification, and Characterization of 
CBP 
 
7.1 Rationale for biophysical characterization  
Although CREB and CBP play key roles in the transcriptional regulation of many 
different target genes, little is known about the protein interactions that drive the 
assembly of the CREB co-activator complex. It remains unclear which member of the co-
activator complex is the predominant regulator of hepatic gluconeogenesis via CREB. 
Additionally, there is still much that we do not know about the binding interactions of 
these proteins at the atomic level.  
Using small fragments of approximately 100 residues of CREB and CBP, the 
structures of the KID domain of CREB and the KIX domain of CBP were previously 
determined using NMR methods [241]. Additionally, the structure of the bZIP domain of 
CREB bound to a cAMP response element was resolved using x-ray crystallography 
[187]. While these structural determination studies provided useful information about 
some of the protein folds they did not provide a comprehensive picture of the long-range 
binding interactions that occur between these two proteins. This work provided useful 
insight into the mechanism of phospho-serine recognition and CREB dimerization but 
failed to describe an actual mechanism for the assembly of the CREB co-activator 
complex. We intend to use larger regions of both proteins in order to identify local 
protein interactions as well as determine the long-range effects of protein interactions. 
Binary complexes of CREB:CBP or CREM:CBP will reveal the necessary binding 




transactivation. These structural studies will allow us to dissect the role of each partner in 
the assembly of the complex and assist us in determining which regions interact to 
mediate CREB-dependent gene transcription. Structural and thermodynamic 
characterization of the protein interactions will be carried out using biophysical methods. 
7.2 Methods 
7.2.1 Cloning, expression, and purification of CBP in bacterial cells 
Two constructs of CBP were cloned into pET vectors (Novagen) containing 
truncated forms of the gene. The shorter of the two constructs corresponded to amino 
acid residues 302-680, while the longer of the two constructs spanned amino acid 
residues 1-680. PCR amplification was performed using Faststart HiFidelity Enzyme 
Blend (Roche) and the following primers for the short construct forward 5’-GAGAGCTC 
ATGGTCAATAGTTTACCTGCTT-3’and reverse 5’-GAGCGGCCGCTCAGTTACCC 
AGGATGCCTTGCTTAT-3’; primers for the longer construct forward 5’-GAGAG 
CTCATGGCCGAGAACTTGCTGGA-3’ and reverse 5’-GAGCGGCCGCTCAGTTAC 
CAGGATGCCTTGCTTAT-3’. The PCR amplified insert was cloned into the TOPO 
vector (Invitrogen), and plasmid DNA containing the cloned gene was purified and 
sequenced. The gene and vectors were digested with restriction enzymes NotI and SacI 
(New England Biolabs) and cloned into pET-28a and pET-42a using these restriction 
sites. The digested ends of insert and vector were joined using T4 ligase (New England 
Biolabs). Following heat inactivation for 15 minutes at 60°C, ligation products were 
transformed into DH5! cells. Several colonies were selected for isolation of plasmid 
DNA using QiaPrep Spin Miniprep Kit (Qiagen). DNA sequencing was used to confirm 




Additionally, a truncated form of the gene corresponding to amino acid residues 1-
680 was also cloned into BamHI and NotI restriction sites of a modified pET-28b vector 
containing Smt3, a protein related to the small ubiquitin-like modifier (SUMO) family of 
proteins. This vector was a gift from the laboratory of Dr. Christopher Lima (Sloan-
Kettering Institute for Cancer Research). Briefly, insert was cloned into the TOPO vector 
(Invitrogen) following PCR amplification with forward primer 5’-GAGAGCTCATG 
GCCGAGAACTTGCTG-3’ and reverse primer 5’-GAAAGCTTTCAGTTACCCAG 
GATGCCTTGCTT-3’. The reading frame was verified by sequencing and plasmid DNA 
was isolated using GeneJet Plasmid Miniprep Kit (ThermoScientific). The vector and 
insert were digested with BamHI and NotI, and ligation followed as outlined above. 
Plasmid DNA of CBP constructs was used to transform E. coli BL21 (DE3) cells 
(Novagen). Cells were grown overnight at 37°C in LB medium supplemented with 100 
µg/mL kanamycin and 10 mL were used to inoculate each liter of Autoinduction Media 
containing the following: 1% tryptone, 0.5% yeast extract, 25 mM Na2HPO4, 25 mM 
KH2PO4, 50 mM NH4Cl, 5 mM Na2SO4, 2 mM MgSO4, 54 mM glycerol, 2.8 mM 
glucose, and 5.6 mM !-lactose. Cells were grown at 18°C, protein expression was auto-
induced, and growth continued overnight. Cells were harvested by centrifugation and 
washed with 50 mM sodium phosphate pH 8.0, 300 mM NaCl, 10 mM imidazole, and 10 
mM "-mercaptoethanol. Following this wash step, cells were subsequently pelleted and 
stored at %80°C. 
After thawing, cells were resuspended in lysis buffer: 50 mM sodium phosphate pH 
8.0, 300 mM NaCl, 10 mM imidazole, and 10 mM "-mercaptoethanol, with one 




microfluidization. Cellular debris was pelleted and removed by centrifugation on a 
Sorvall GSA rotor for 40 minutes at 12,000 rpm. The lysate was filtered through a 0.2 µm 
filter and loaded onto a HisTrap HP 5 mL column (GE Healthcare) pre-equilibrated with 
buffer containing 50 mM sodium phosphate pH 8.0, 300 mM NaCl, 10 mM imidazole, 
and 10 mM "-mercaptoethanol. Unbound proteins were washed for 5 column volumes 
with this buffer. Segmented imidazole gradient was used to elute protein with 30-100% 
of buffer containing 50 mM sodium phosphate pH 8.0, 300 mM NaCl, 250 mM 
imidazole, and 10 mM "-mercaptoethanol, to 30% over 20 column volumes, followed by 
holding step for 5 column volumes, with subsequent gradient to 100% over 20 column 
volumes in final step (Figure 64).  
Fractions containing protein were pooled and dialyzed using 10 kD MWCO 
membrane (Pierce Snakeskin) against an excess of buffer containing 20 mM Tris-Cl pH 
8.0, 300 mM NaCl, 5 mM "-mercaptoethanol, and Ulp1 protease was added to protein at 
4°C with agitation overnight. The following morning, protein was dialyzed against an 
excess of buffer containing 20 mM Tris-Cl pH 8.0, 50 mM NaCl, and 5 mM "-
mercaptoethanol. Subsequently, protein was loaded onto Source Q column (GE 
Healthcare) pre-equilibrated with filtered dialysis buffer to separate protein from tag. 
Elution buffer containing 20 mM Tris-Cl pH 8.0, 1 M NaCl, and 5 mM "-
mercaptoethanol was used to elute uncleaved protein and bound tag from column. 
Unbound flow-through fractions containing tag-free protein were pooled and analyzed 
using SDS-PAGE analysis (Figure 65). 
Protein fractions were analyzed by SDS-PAGE, and subsequently pooled and 




0.05 mM ZnCl2, and 10 mM "-mercaptoethanol for a total of 4 hours. The dialysis buffer 
was filtered through a 0.2 µm filter and used as the equilibration and binding buffer for 
the next step of purification. The protein was further purified using cation exchange 
chromatography over a Source S column (GE Healthcare). Unbound proteins were 
washed with 4 column volumes of buffer A with target protein eluted with a gradient to 
100% of buffer B (100 mM MES pH 6.0, 1 M NaCl, 0.05 mM ZnCl2, and 10 mM "-
mercaptoethanol) over 20 column volumes (Figure 66). Fractions of protein containing & 
95% purity were collected and concentrated to 4-10 mg/mL, and stored at %80 °C. 
7.2.2 Cloning and expression of CBP in insect cells 
CBP (1-680) was cloned into the pBiEx1 vector using NotI and SacI as restriction 
sites using the same methods as outlined previously for cloning into pET vectors. Sf9 
cells were grown to approximately 2.5 ( 106 cells/mL in 2.5 L of serum-free 
Sf900IIISFM media (Invitrogen) without antibiotics. Plasmid DNA was added to serum-
free media in a ratio of 1:2000 (420 µg DNA added to 84 mL of media) mixed by 
inversion, and filtered using 0.2 µm acetate syringe filters (Nalgene). A 250 µg/mL stock 
of cationic lipid, dimethyldioctadecylammonium bromide (DDAB), was prepared. 
DDAB was added to serum-free media in a 1:1 ratio (42 mL of each) and the liposome-
DNA complexes were formed by the addition of DNA drop-wise to lipid, and the 
solution was mixed gently. Liposome-DNA complexes were incubated at room 
temperature for 20 minutes to allow binding of DNA to the liposome before adding to 
insect cells. The following day, 5% fetal bovine serum (FBS), and 1X stocks of penicillin 




hours. The Sf9 cells were harvested by centrifugation at 1000 rpm for 15 minutes at 10°C 
and pellets stored at %80°C.  
7.2.3 Purification from insect cells  
Insect cell pellets were thawed in a beaker containing room temperature water and 
resuspended in buffer containing 50 mM sodium phosphate pH 8.0, 300 mM NaCl, 10 
mM imidazole, 0.1% Triton X-100, 10 mM "-mercaptoethanol, with one dissolved 
Complete EDTA-free protease inhibitor tablet (Roche). Sonication was used to lyse cells 
at a 25% duty cycle for 1min with three second pulses and a one second pause in between 
pulses. Cellular debris was pelleted by centrifugation at 18,000 rpm at 4°C for 30 minutes 
using a Sorvall SS-34 rotor. The soluble cytoplasmic fraction was filtered with 0.2 µm 
SFCA-PF syringe filters (Corning) followed by another filtering step using 0.2 µm 
Stericup filters (Millipore). Protein lysate was incubated with 1 mL of a 50/50 slurry of 
Ni-NTA agarose beads (Qiagen) for 2 hours at 4°C with agitation. Beads were pelleted at 
low speed using centrifugation and washed with binding buffer (50 mM sodium 
phosphate pH 8.0, 300 mM NaCl, 10 mM imidazole, and 10 mM "-mercaptoethanol), for 
three 5 mL washes. Protein was eluted stepwise with 1 mL of buffer containing 50 mM 
sodium phosphate pH 8.0, 300 mM NaCl, and 10 mM "-mercaptoethanol with varying 
concentrations of imidazole (50 mM, 100 mM, 150 mM, or 250 mM) for a total of 12 
washes. Fractions were analyzed by SDS-PAGE (Figure 67). 
7.2.4 Screening of crystallization conditions 
Recombinant protein was expressed from bacterial cells. CBP was screened for 




nL of protein were mixed with 300 nL of reservoir solution using the Mosquito (TTP 
Labtech). The following screens were used: Natrix Screen HT (Hampton Research), 
MPD (Qiagen), Crystal Screen I and II, Salt Rx HT, PEGRx HT (Hampton Research), 
and JSCG (Jena Bioscience). The total reservoir volume was 100 µL and trays were 
incubated at 20°C. 
7.2.5 Electrophoretic Mobility Shift Assay 
Electrophoretic mobility shift assay (EMSA) was performed with CREB, CBP, and 
CREM recombinant proteins and 32P-labeled DNA fragments. Proteins were synthesized 
using the TNT coupled transcription and translation reticulocyte lysate system with T7 
polymerase (Promega), according to the manufacturer’s protocol. Reaction components 
(Table 7) were assembled and incubated at 30°C for 90 minutes. In order to assess 
CREB-CBP binding and CREM-CBP binding, a consensus cAMP response element 
(CRE) DNA binding site was generated using the following primers: sense 5’-CCTTGG 
CTGACGTCAGCCAAG-3’, as well as antisense 5’-CTTGGCTGACGTCAGCCA 
AGG-3’. These oligonucleotides were #32P-end labeled with T4 polynucleotide kinase. 
For each EMSA, in vitro translated proteins were mixed with radiolabeled probe for 30 
minutes at room temperature, along with deoxyinosine-deoxycytosine, salmon sperm, and 
binding buffer containing 50 mM potassium chloride, 20% glycerol, and 20 mm HEPES 
(pH 7.6-7.8). Binding was competed by addition of the unlabeled oligonucleotide in 
excess. Gel electrophoresis was used to separate each sample on a 5% nondenaturing 






Table 7. TNT Reaction Components for EMSA 
Reaction Components Amount Used 
TNT Rabbit Reticulocyte Lysate 25 µL 
TNT Reaction Buffer 2 µL 
TNT RNA Polymerase 1 µL 
Amino Acid Mixture, Minus Leucine, 1 mM 0.5 µL 
Amino Acid Mixture, Minus Methionine, 1 mM 0.5 µL 
RNasin Ribonculease Inhibitor (40 u/µL) 1 µL 
DNA Templates (0.5 µg/µL) 2 µL 
Transcend Biotin-Lysyl-tRNA 1 µL 
Nuclease-free ddH2O to final volume 50 µL 
 
7.2.6 Limited proteolysis of CBP-CREM complex 
Stocks of protein and protease were dissolved in the following buffer: Tris-Cl pH 
8.0, 150 mM NaCl, and 10 mM BME. Reactions were prepared with CREM, CBP, 
CREM and CRE, CBP and CRE, or with a combination of all three to map binding 
interactions in the presence of trypsin. Equivalent amounts of CREM and CBP were used 
in each reaction (2.8 nanomoles), and trypsin was used at a final concentration of 1 µg/µL 
in a total reaction volume of 550 µL. MgCl2 (2.5 mM) was added to all reactions 
containing equimolar amounts of the DNA duplex CRE. Following the addition of 
trypsin, reactions were allowed to proceed on ice, and samples were taken at 3 minutes, 
60 minutes, and overnight. Following SDS-PAGE analysis (Figure 68) samples were 




7.2.7 Gel Filtration of CBP and CREM 
Gel filtration chromatography was used to characterize the binding interactions 
between CBP and CREM. CREM, CBP, and equimolar amounts of CBP and CREM 
were loaded onto a Superose 12 10/300 GL column (GE Healthcare) and eluted in one 
column volume with buffer containing 20 mM Tris-Cl pH 8.0, 150 mM NaCl, 10 mM "-
mercaptoethanol (Figure 69). Fractions of CREM corresponding to the peak were 
concentrated to 10-12 mg/mL, and fractions of CBP were concentrated to 5-10 mg/mL 
for storage at %80°C. 
 
Table 8. Expression systems utilized for production of CBP protein. 
Construct Expression System Problem 
pET42a-CBP302-680 T7 Precipitates easily 
pET28a-CBP302-680 T7 Precipitates easily 
pET42a-CBP1-680 T7 Precipitates easily 
pET28a-CBP1-680 T7 Precipitates easily 
pBiEx-3BS-CBP1-680 Insect No expression 
His6-Smt3-CBP1-680 T7 *No problem 
*Construct was well-behaved. 
 
7.2.7 Isothermal Calorimetry of CBP and CREM 
The binding interactions of CBP and CREM were studied using isothermal titration 
calorimetry (ITC) using a VP-ITC instrument (Microcal Inc.). Both proteins were 
dialyzed overnight against 1 L of buffer containing: 25 mM HEPES pH 7.5, 300 mM 
NaCl, 5 mM MgCl2, and 1 mM TCEP. Subsequently, dialysis buffer was filtered using a 
0.2 µm filter and used in the binding experiments. All solutions were degassed 




with dialysis buffer. In each case, these calculations were based on the molecular weight 
of the monomer following assessment of protein concentration. In the sample cell, 1.4 
mL of CBP was titrated with twenty-four 10 µL injections of CREM, after an initial 2 µL 
injection. CREM was added at 3.5 minute intervals with stirring at 300 rpm. Experiments 
were performed at 27°C, using a reference power of 5 µCal/second. The MicroCal 
ORIGIN software package 5.0 was used to analyze data. The enthalpy of binding was 
determined based on the heat released. 
7.3 Results and Discussion 
In these studies we attempted to use a construct of CBP encompassing multiple 
domains, and a construct of full-length CREB in order to identify local protein 
interactions as well as determine the long-range effects of protein-protein interactions 
between these two proteins. Binary complexes of CREB:CBP or ternary complexes of 
CREB:CRE:CBP would reveal the necessary binding interactions that must occur for 
complex assembly and for the induction of CREB transactivation. Structural studies 
would have allowed us to dissect the role of each partner in the assembly of the complex 
and assist us in determining which regions interact to mediate CREB-dependent gene 
transcription.  
Despite the use of several different constructs and expression systems (Table 8), X-
ray quality crystals were not obtained. The soluble monomeric tag Smt3/SUMO has been 
shown to increase protein solubility [242], and we observed an increase in overall yield 
with this construct in comparison to all other CBP constructs. However no crystallization 




In addition, we employed several different methods to assess the binding 
interactions of CBP and CREM. EMSA, limited proteolytic cleavage assay, gel filtration, 
and ITC were all utilized. For the experiments with EMSA, there were no gel shifts 
indicating a lack of interaction between CBP and CREM. The results from the proteolytic 
cleavage assay followed by N-terminal sequencing, and from the gel filtration 
experiments were promising. These results indicated that CBP delays the proteolytic 
cleavage of CREM. In its absence CREM was more accessible, and the N-terminal 
sequencing results demonstrated that C-terminal arginine residues present in CREM were 
available for digestion by trypsin. CREM contains a kinase inducible domain and it 
seemed to bind CBP through this region. This interaction had a protective effect against 
digestion. Additionally, in the gel filtration studies, there was a shift in the peak when 
CREM and CBP were combined in equimolar amounts in comparison to the peak 
observed for either protein alone. 
By employing ITC, we attempted to map the binding site of CBP and CREM, as 
well as confirm the binding interactions we observed during gel filtration and proteolytic 
cleavage experiments with trypsin. We had hoped to gain information about the binding 
affinity and to detect the presence of multiple or different binding sites between CBP and 
CREM. However, ITC experiments only indicated heats of dilution rather than the 
enthalpy of binding (data not shown). 
Additionally we used the XtalPred web server to predict the crystallizability of 
CBP [229]. A prediction was made based on a comparison of different protein features 




degree of difficulty and the results are summarized (Figure 70). It contains a long 






Figure 64. Ni2+-affinity chromatography of CBP. 
(A) Chromatogram of CBP purification. The blue line denotes absorbance at 280 nm in 
milliabsorbance units on the left and the green line represents gradient of buffer used for 
elution with concentration listed on right axis. Pink line denotes sample injection. (B) 
SDS-PAGE gel of purification stained with Coomassie blue stain. M refers to molecular 
weight ladder in kilodaltons, P refers to insoluble pellet, L to sample loaded onto column, 
FT to unbound protein. Fractions pooled for dialysis are shown. 
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Figure 65. Anion exchange chromatography of CBP after Ulp1 cleavage.
(A) Chromatogram of second step of CBP purification. The blue line denotes absorbance 
at 280 nm in milliabsorbance units on the left and the green line represents gradient of 
buffer used for elution with concentration listed on right axis. Pink line denotes sample 
injection. (B) SDS-PAGE gel of purification stained with Coomassie blue stain. M refers 
to molecular weight ladder in kilodaltons and L to sample loaded onto column, FT refers 
to unbound/tag-free protein. Fractions 5-23 were pooled and dialyzed for next step. 
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Figure 66. Cation exchange chromatography of CBP. 
(A) Chromatogram of last step of CBP purification. The blue line denotes absorbance at 
280 nm in milliabsorbance units and the green line represents gradient of buffer used for 
elution. Pink line denotes sample injection. (B) SDS-PAGE gel of purification stained 
with Coomassie blue stain. M refers to molecular weight ladder in kilodaltons and L to 
sample loaded onto column. Fractions corresponding to peak are shown. 
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Figure 67. Ni2+-affinity chromatograpy of CBP using Ni-NTA agarose beads.  
SDS-PAGE gel displaying purification of CBP from insect cell lysate. The gel was 
stained with Coomassie blue stain. M refers to molecular weight ladder in kilodaltons, T 
refers to total lysate, L refers to sample loaded onto column, FT to unbound protein, W 
refers to wash steps, and successive elution steps are also displayed. 
 
Figure 68. CBP protects CREM from proteolytic cleavage. 
SDS PAGE analysis after incubation with trypsin. (A) CBP and CREM after 3 minutes; 
(B) CBP and CREM after 60 minutes; (C) CBP and CREM overnight; (D) molecular 
weight, (E) CBP, CREM, CRE after 3 minutes; (F) CBP, CREM, CRE after 60 minutes; 
(G) CBP, CREM, CRE overnight; (H) CREM and CRE after 3 minutes; (I) CREM and 
CRE after 60 minutes; (J) CREM and CRE overnight. 
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Figure 69. CBP and CREM interact. 
Peaks shift upon interaction. (A) Gel filtration chromatography of CBP. (B) Gel filtration 
chromatography of CREM. (C) Gel filtration chromatography of CREM and CBP. 
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Figure 70. Crystallization probability analysis of CBP. 
(A) Histograms representing comparison of target features with distribution probabilities 
obtained for: length, isoelectric point, gravity index, length of disordered regions, 
instability, percentage of coil structures, and number of coiled coils displayed for CBP. 
(B) Crystallization class with length, gravity index, instability index, and longest 
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